Abdominal Closure with Antibacterial Coated Suture Materials and Its Relation to the Incidence of Post Operative Superficial Surgical Site Infection Rates by Karthikeyan, R
ABDOMINAL CLOSURE WITH ANTIBACTERIAL COATED SUTURE 
MATERIALS AND ITS RELATION TO THE INCIDENCE OF POST 
OPERATIVE SUPERFICIAL SURGICAL SITE INFECTION RATES 
 
  
DISSERTATION SUBMITTED TO 
THE TAMILNADU DR.M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
In partial fulfilment of 
the requirements for the degree of 
MASTER OF SURGERY 
In 
GENERAL SURGERY 
 
DEPARTMENT OF GENERAL SURGERY 
TIRUNELVELI MEDICAL COLLEGE 
TIRUNELVELI 
APRIL-2017 
2 
 
 
CERTIFICATE BY THE GUIDE 
 
This is to certify that the dissertation entitled “ABDOMINAL CLOSURE 
WITH ANTIBACTERIAL COATED SUTURE MATERIALS AND ITS 
RELATION TO THE INCIDENCE OF POST OPERATIVE 
SUPERFICIAL SURGICAL SITE INFECTION RATES” is a bonafide 
research work done by DR. R.KARTHIKEYAN, Post Graduate M.S student in 
Department of General Surgery, Tirunelveli medical college & Hospital, 
Tirunelveli, in fulfilment of the requirement for the degree of Master of Surgery 
in General Surgery. 
 
 
 
 
  Prof. Dr.R.MAHESWARI M.S., 
Date:                  Professor and HOD 
  Department of General Surgery, 
Place: Tirunelveli      Tirunelveli Medical College & Hospital, 
       Tirunelveli. 
 
 
 
 
3 
 
 
 
CERTIFICATE BY THE HEAD OF THE DEPARTMENT 
This is to certify that the dissertation entitled “ABDOMINAL CLOSURE 
WITH ANTIBACTERIAL COATED SUTURE MATERIALS AND ITS 
RELATION TO THE INCIDENCE OF POST OPERATIVE 
SUPERFICIAL SURGICAL SITE INFECTION RATES” is  bonafide and 
genuine research work carried out by DR. R. KARTHIKEYAN, Post Graduate 
M.S student in Department of General Surgery, Tirunelveli medical college & 
Hospital, Tirunelveli under the guidance of Dr. R. MAHESWARI M.S. 
Professor, Department of General Surgery, Tirunelveli Medical College 
Tirunelveli in partial fulfilment of the requirements for the degree of M.S in 
GENERAL SURGERY. 
 
 
 
 
 
 
Date:       Prof. Dr. R. MAHESWARI M.S., 
Place: Tirunelveli     Professor and HOD, 
Department of General Surgery, 
Tirunelveli medical college & Hospital, 
Tirunelveli. 
4 
 
 
CERTIFICATE BY THE HEAD OF INSTITUTION 
This is to certify that the dissertation entitled “ABDOMINAL CLOSURE 
WITH ANTIBACTERIAL COATED SUTURE MATERIALS AND ITS 
RELATION TO THE INCIDENCE OF POST OPERATIVE 
SUPERFICIAL SURGICAL SITE INFECTION RATES” is a bonafide and 
genuine research work carried out by DR. R. KARTHIKEYAN, Post Graduate 
M.S student in Department of General Surgery, Tirunelveli medical college & 
Hospital, Tirunelveli under the guidance of Dr. R. MAHESWARI M.S. 
Professor, Department of General Surgery, Tirunelveli Medical College, 
Tirunelveli in partial fulfilment of the requirements for the degree of M.S in 
GENERAL SURGERY. 
 
 
 
 
Date:      Dr. SITHY ATHIYA MUNAVARAH M.D., 
Place: Tirunelveli    The Dean, 
Tirunelveli medical college & Hospital, 
Tirunelveli. 
 
 
5 
 
 
 
 
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
 
DEPARTMENT OF GENERAL SURGERY 
TIRUNELVELI MEDICAL COLLEGE 
TIRUNELVELI-627011 
 
 
 
DECLARATION BY THE CANDIDATE 
 
I hereby declare that the dissertation entitled “ABDOMINAL CLOSURE 
WITH ANTIBACTERIAL COATED SUTURE MATERIALS AND ITS 
RELATION TO THE INCIDENCE OF POST OPERATIVE 
SUPERFICIAL SURGICAL SITE INFECTION RATES” is a bonafide and 
genuine research work carried out by me under the guidance of                                  
Dr. R. MAHESWARI M.S. Professor, Department of General Surgery, 
Tirunelveli Medical College, Tirunelveli. 
 
 
 
 
 
 
 
 
Dr. R. KARTHIKEYAN, 
Date:       Postgraduate in General Surgery, 
Place: Tirunelveli     Tirunelveli Medical College & Hospital, 
Tirunelveli. 
 
8 
 
 
ACKNOWLEDGEMENT 
I express my deep sense of gratitude and indebtedness to my respected 
teacher and guide Dr.R.MAHESWARI M.S. Professor, Department of General 
Surgery, Tirunelveli Medical College, Tirunelveli, whose valuable guidance and 
constant help have gone a long way in the preparation of this dissertation.  
I express my sincere thanks to Professors Dr.K.Rajendran M.S, 
Dr.Pandy M.S, Dr.Varadarajan M.S, Dr. Alex Arthur Edward M.S, Dr. 
Sridhar M.S, Dr. Edwina Vasantha M.S, and Dr. Shanti Nirmala M.S for 
their valuable advice and support.  
I am also thankful to Assistant Professors Dr.K.J.P.Selvi M.S, 
Dr.Sivanupandian M.S, and Dr.Nagalakshmi M.S for their help.  
I also thank Professor Dr. Revathy MD   and faculty members of 
Department of Microbiology for their guidance. 
 I express my thanks to all of the staff members of the Department Of 
General Surgery and all my Postgraduates colleagues and friends for their help 
during my study and preparation of this dissertation and also for their co-
operation. 
 I always remember my family members for their everlasting blessings and 
encouragement. 
 Lastly, I express my thanks to my patients without whom this study would 
not have been possible. 
 
Dr. R. KARTHIKEYAN, 
Postgraduate in General Surgery, 
9 
 
Date:       Tirunelveli Medical College, 
Place: Tirunelveli     Tirunelveli. 
CONTENTS 
 
S. No TITLE 
PAGE NO. 
 
1 
 
 
INTRODUCTION 
 
10 
2 
 
 
AIM OF THE STUDY 
 
14 
3 
 
 
METHODOLOGY 
 
16 
4 
 
 
REVIEW OF LITERATURE 
 
20 
5 
 
 
OBSERVATION AND RESULTS 
 
78 
6 
 
DISCUSSION 
 
89 
7 
 
CONCLUSION 
 
93 
8 
 
BIBLIOGRAPHY 
 
95 
 
 
ANNEXURES: 
I. PHOTOS 
II. PROFORMA 
III. CONSENT FORM 
108 
109 
110 
111 
112 
10 
 
IV. MASTER CHART 
V. KEY TO MASTER CHART 
114 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
 
 
 
 
11 
 
 
 
 
 
INTRODUCTION 
Surgical site infection (SSI) is an immense burden on healthcare resources 
even in the modern era of immaculate sterilization approaches and highly 
effective antibiotics. An estimated 234 million various surgical procedures, 
involving skin incisions requiring various types of wound closure techniques, are 
performed in the world, with the majority resulting in a wound healing by primary 
intention.  
The most widely recognized definition of infection, which is used 
throughout the United States and Europe, is that devised and adopted by the 
Centre for Disease Control and Prevention. An SSI is defined as an infection 
occurring within 30 days of surgery that meets the following criteria: (1) the 
diagnosis consists of the infection of an anatomic plane by one of the following 
manifestations: collection, inflammatory signs (pain, edema, tenderness, 
redness), dehiscence, or positive culture; and (2) classification according to the 
anatomic plane as follows: superficial incisional SSI, infection of the skin and 
subcutaneous tissue; deep incisional SSI, infection of the deep soft tissue (fascia 
and muscles); and organ/space SSI, infection of the organ/space. In this study, 
SSIs were categorized by the above classifications.  
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A system of classification for surgical wounds that is based on the degree 
of microbial contamination was developed by the US National Research Council 
group in 1964. Four wound classes with an increasing risk of SSI were described: 
clean, clean-contaminated, contaminated, and dirty. In this study, SSIs were 
researched based on each of the wound classes. 
Skin wounds are at risk of SSI and therefore may lead to increased 
morbidity, delayed recovery and prolonged hospital stay. The prevalence of SSI 
in the developed world is variable but reported figures are estimated at around 
5%. The development of SSI is a multifactorial phenomenon, which requires a 
multimodal approach to prevent and treat it in a timely manner to avoid financial, 
psychological and health-related quality of life consequences. Various 
predisposing aetiopathological factors for SSI include immunosuppression, 
nutritional deficiencies, hypoproteinemias, congestive cardiac failure, and 
hepatic failure, and renal failure, use of steroids, chemotherapy agents, steroids 
and diabetes mellitus. In additions to these factors, wound contamination, 
contaminated instruments, surgical technique and sutures used to close skin have 
also been reported to be responsible for SSI and cosmetic outcomes. The 
prevention of the SSI by various invasive and non-invasive interventions is the 
most common measure surgeons and other healthcare professional advocate to 
tackle the problem of SSI. This includes use of prophylactic antibiotics and 
various other multimodal approaches already reported in the medical literature. 
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Triclosan [5-chloro-2-(2, 4-dichlorophenoxy) phenol] is a broad-spectrum 
bacteriocidal agent that has been used for more than 40 years in various products, 
such as toothpaste and soaps. Higher concentrations of triclosan work as a 
bactericide by attacking different structures in the bacterial cytoplasm and cell 
membrane. At lower concentrations, triclosan acts as bacteriostatic agent, binding 
to enol-acyl reductase (ENR), a product of the Fab I gene and thus inhibiting fatty 
acid synthesis. Use of triclosan-coated sutures should theoretically result in the 
reduction of SSI. Several studies have shown a reduction in the number of 
bacteria in vitro and also of wound infections in animals.  
The aim of this study was to evaluate whether the incidence of SSIs can be 
reduced when triclosan coated sutures are used for the closure of the fascia, and 
to evaluate the incidence of SSIs according to each wound classification 
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AIMS AND OBJECTIVES OF THE STUDY 
AIM OF THE STUDY 
To assess abdominal closure with antibacterial coated suture materials and its 
relation to the incidence of post-operative superficial surgical site infection rates. 
OBJECTIVES OF THE STUDY 
1. To compare the incidence of superficial SSI in laparotomy incisions closed 
with coated polyglactin910 suture with triclosan versus incisions closed with 
coated polyglactin910 suture without triclosan 
2. To study the time frame between surgery and development of SSI 
3. To determine which bacteria is commonly associated with SSI after 
laparotomy closure 
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MATERIALS AND METHODS 
SOURCE OF DATA    
      1) The data will be collected from hospital records of surgery performed, post-
operative daily progress notes and outpatient folders and telephonic conversations 
with patients after discharge  
      2) Type of subject: all patients undergoing emergency laparotomy procedure 
for any cause. 
      3) Choosing subjects: number to be studied: 70-divided as 35 in each group. 
This number was chosen keeping in mind the time restrictions of the study, the 
feasibility and ease of calculations. 
Inclusion criteria:  
1) All patients above the age of 18yrs requiring a laparotomy 
          2) All superficial SSI (skin and subcutaneous layer only) developing within 
a 30 day period post-surgery, as per the traditional definition. 
Exclusion criteria: 
 1) Patients<18 yrs. of age 
  2) Deep SSI or Organ space SSI 
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  3) Wound infections occurring beyond the 30 day time period post-surgery. 
 
 
METHOD OF COLLECTION OF DATA 
        1) The pre-operative data collected will include the patient’s demographics, 
co-morbidities, laparotomy indication, setting (emergency/elective) and class of 
wound. Intra-operative data will include the method of painting and draping, 
duration of the surgery, antibiotics received during surgery, intra-operative 
findings which will help in classifying the wound (eg: biliary contamination) 
Post-operative data include development of superficial SSI as per the 
standardized means of detecting and diagnosing superficial surgical site 
infections, and if they did, what organism did the wound swab grow, and how 
many days after laparotomy did they develop the SSI. 
      2) The study planned is an observational study. All individuals admitted in 
one surgical unit undergoing laparotomy will have closure of subcutaneous layer 
with coated polyglactin 910 with triclosan. All individuals undergoing 
laparotomy in other surgical units will have closure of subcutaneous closure with 
coated polyglactin 910 without triclosan. These patients will be followed up for 
a period of one month post-surgery and the above mentioned data will be 
collected. 
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     3) The superficial SSI rates will be reported as percentages within each group 
and compared between the groups using t-test for proportion. 
          The time frame between surgery and development of superficial SSI will 
be summarized as mean and standard deviation. This will be compared between 
the two groups using independent sample t-test, if the data is normally distributed. 
          The commonly observed bacteria in the 2 groups will be listed as number 
and percentage.  
           All statistical tests will be considered significant at p<0.05 level of 
significance. 
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REVIEW OF LITERATURE 
SURGICAL SITE INFECTIONS 
HISTORICAL ASPECTS 
The ancient Egyptians were the first civilization to have trained clinicians 
to treat physical ailments. Medical papyri, such as the Edwin Smith papyrus (circa 
1600 BCE) and the Ebers papyrus (circa 1534 BCE), provided detailed 
information of management of disease, including wound management with the 
application of various potions and grease to assist healing.[1, 2]  
Hippocrates (Greek physician and surgeon, 460-377 BCE), known as the 
father of medicine, used vinegar to irrigate open wounds and wrapped dressings 
around wounds to prevent further injury. His teachings remained unchallenged 
for centuries. 
Galen (Greek surgeon to Roman gladiators, 130-200 CE) was the first to 
recognize that pus from wounds inflicted by the gladiators heralded healing (pus 
bonum et laudabile ["good and commendable pus"]). 
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Unfortunately, Galen's observation was misinterpreted, and the concept of 
pus pre-empting wound healing persevered well into the 18th century. The link 
between pus formation and healing was emphasized so strongly that foreign 
material was introduced into wounds to promote pus formation-suppuration. The 
concept of wound healing remained a mystery, as highlighted by the famous 
saying by Ambroise Paré (French military surgeon, 1510-1590), "I dressed the 
wound. God healed it."[3]  
The scale of wound infections was most evident in times of war. During 
the American Civil War, erysipelas (necrotizing infection of soft tissue) and 
tetanus accounted for over 17,000 deaths, according to an anonymous source in 
1883. Because compound fractures at the time almost invariably were associated 
with infection, amputation was the only option, despite a 25-90% risk of 
amputation stump infection. 
Koch (Professor of Hygiene and Microbiology, Berlin, 1843-1910) first 
recognized the cause of infective foci as secondary to microbial growth in his 
19th century postulates. Semmelweis (Austrian obstetrician, 1818-1865) 
demonstrated a fivefold reduction in puerperal sepsis by hand washing between 
performing post-mortem examinations and entering the delivery room. 
Joseph Lister (Professor of Surgery, London, 1827-1912) and Louis 
Pasteur (French bacteriologist, 1822-1895) revolutionized the entire concept of 
wound infection. Lister recognized that antisepsis could prevent infection. [4] In 
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1867, he placed carbolic acid into open fractures to sterilize the wound and to 
prevent sepsis and hence the need for amputation. In 1871, Lister began to use 
carbolic spray in the operating room to reduce contamination. However, the 
concept of wound suppuration persevered even among eminent surgeons such as 
John Hunter. [5]  
World War I resulted in new types of wounds from high-velocity bullet 
and shrapnel injuries coupled with contamination by the mud from the trenches. 
Antoine Depage (Belgian military surgeon, 1862-1925) reintroduced wound 
debridement and delayed wound closure and relied on microbiological 
assessment of wound brushings as guidance for the timing of secondary wound 
closure.[6] Alexander Fleming (microbiologist, London, 1881-1955) performed 
many of his bacteriologic studies during World War I and is credited with the 
discovery of penicillin. 
As late as the 19th century, aseptic surgery was not routine practice. 
Sterilization of instruments began in the 1880s as did the wearing of gowns, 
masks, and gloves. Halsted (Professor of Surgery, Johns Hopkins University, 
United States, 1852-1922) introduced rubber gloves to his scrub nurse (and future 
wife) because she was developing skin irritation from the chemicals used to 
disinfect instruments. The routine use of gloves was introduced by Bloodgood, a 
student of Halsted. 
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Penicillin first was used clinically in 1940 by Howard Florey. With the use 
of antibiotics, a new era in the management of wound infections commenced. 
Unfortunately, eradication of the infective plague affecting surgical wounds has 
not ended because of the insurgence of antibiotic-resistant bacterial strains and 
the nature of more adventurous surgical intervention in immunocompromised 
patients and in implant surgery. 
PATHOPHYSIOLOGY 
Wound healing is a continuum of complex interrelated biologic processes 
at the molecular level. For descriptive purposes, healing may be divided into the 
following three phases: 
 Inflammatory phase  
 Proliferative phase  
 Maturation phase  
Inflammatory phase 
The inflammatory phase commences as soon as tissue integrity is disrupted 
by injury; this begins the coagulation cascade to limit bleeding. Platelets are the 
first of the cellular components that aggregate to the wound, and, as a result of 
their degranulation (platelet reaction), they release several cytokines (or paracrine 
growth factors). These cytokines include platelet-derived growth factor (PDGF), 
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insulin like growth factor-1 (IGF-1), epidermal growth factor (EGF), and 
fibroblast growth factor (FGF). 
Serotonin is also released, which, together with histamine (released by 
mast cells), induces a reversible opening of the junctions between the endothelial 
cells, allowing the passage of neutrophils and monocytes (which become 
macrophages) to the site of injury. 
This large cellular movement to the injury site is induced by cytokines 
secreted by the platelets (chemotaxis) and by further chemotactic cytokines 
secreted by the macrophages themselves once at the site of injury. These include 
transforming growth factor alpha (TGF-α) and transforming growth factor beta 
(TGF-β). 
Consequently, an inflammatory exudate that contains red blood cells, 
neutrophils, macrophages, and plasma proteins, including coagulation cascade 
proteins and fibrin strands, fills the wound in a matter of hours. Macrophages not 
only scavenge but they also are central to the wound healing process because of 
their cytokine secretion. 
Proliferative phase 
The proliferative phase begins as the cells that migrate to the site of injury, 
such as fibroblasts, epithelial cells, and vascular endothelial cells, start to 
proliferate and the cellularity of the wound increases. The cytokines involved in 
26 
 
this phase include FGFs, particularly FGF-2 (previously known as basic FGF), 
which stimulates angiogenesis and epithelial cell and fibroblast proliferation. 
The marginal basal cells at the edge of the wound migrate across the 
wound, and, within 48 hours, the entire wound is epithelialized. In the depth of 
the wound, the number of inflammatory cells decreases with the increase in 
stromal cells, such as fibroblasts and endothelial cells, which, in turn, continue to 
secrete cytokines. Cellular proliferation continues with the formation of 
extracellular matrix proteins, including collagen and new capillaries 
(angiogenesis). This process is variable in length and may last several weeks. 
Maturation phase 
In the maturation phase, the dominant feature is collagen. The dense bundle 
of fibers, characteristic of collagen, is the predominant constituent of the scar. 
Wound contraction occurs to some degree in primary closed wounds but is a 
pronounced feature in wounds left to close by secondary intention. The cells 
responsible for wound contraction are called myofibroblasts, which resemble 
fibroblasts but have cytoplasmic actin filaments responsible for contraction. 
The wound continuously undergoes remodeling to try to achieve a state 
similar to that prior to injury. The wound has 70-80% of its original tensile 
strength at 3-4 months after operation. 
ETIOLOGY 
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 All surgical wounds are contaminated by microbes, but in most cases, 
infection does not develop because innate host defenses are quite efficient in 
the elimination of contaminants. A complex interplay between host, microbial, 
and surgical factors ultimately determines the prevention or establishment of a 
wound infection 
Microbiology 
Microbial factors that influence the establishment of a wound infection are 
the bacterial inoculum, virulence, and the effect of the microenvironment. When 
these microbial factors are conducive, impaired host defenses set the stage for 
enacting the chain of events that produce wound infection. 
Most SSIs are contaminated by the patient's own endogenous flora, which 
are present on the skin, mucous membranes, or hollow viscera. The traditional 
microbial concentration quoted as being highly associated with SSIs is that of 
bacterial counts higher than 10,000 organisms per gram of tissue (or in the case 
of burned sites, organisms per cm2 of wound).[7]  
The usual pathogens on skin and mucosal surfaces are gram-positive cocci 
(notably staphylococci); however, gram-negative aerobes and anaerobic bacteria 
contaminate skin in the groin/perineal areas. The contaminating pathogens in 
gastrointestinal surgery are the multitude of intrinsic bowel flora, which include 
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gram-negative bacilli (eg, Escherichia coli) and gram-positive microbes, 
including enterococci and anaerobic organisms. [8] 
Gram-positive organisms, particularly staphylococci and streptococci, 
account for most exogenous flora involved in SSIs. Sources of such pathogens 
include surgical/hospital personnel and intraoperative circumstances, including 
surgical instruments, articles brought into the operative field, and the operating 
room air. 
The group of bacteria most commonly responsible for SSIs are Staphylococcus 
aureus strains. The emergence of resistant strains has considerably increased the 
burden of morbidity and mortality associated with wound infections. 
Methicillin-resistant Staphylococcus aureus (MRSA) is proving to be the 
scourge of modern-day surgery. Like other strains of S aureus, MRSA can 
colonize the skin and body of an individual without causing sickness, and, in this 
way, it can be passed on to other individuals unknowingly. Problems arise in the 
treatment of overt infections with MRSA because antibiotic choice is very 
limited. MRSA infections appear to be increasing in frequency and are displaying 
resistance to a wider range of antibiotics.[9]  
Of particular concern are the vancomycin intermediate S aureus (VISA) 
strains of MRSA. These strains are beginning to develop resistance to 
vancomycin, which is currently the most effective antibiotic against MRSA. This 
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new resistance has arisen because another species of bacteria, called enterococci, 
relatively commonly express vancomycin resistance. 
Risk factors (other than microbiology)    
 Decreased host resistance can be due to systemic factors affecting the 
patient's healing response, local wound characteristics, or operative 
characteristics, as follows: 
 Systemic factors - Age, malnutrition, hypovolemia, poor tissue perfusion, 
obesity, diabetes, steroids, and other immunosuppressants  
 Wound characteristics - Nonviable tissue in wound, hematoma, foreign 
material, poor skin preparation (eg, shaving), and preexistent sepsis.  
 Operative characteristics - Poor surgical technique; lengthy operation (>2 
hours); intraoperative contamination (eg, from infected theater staff and 
instruments or inadequate theater ventilation), prolonged preoperative stay 
in the hospital, and hypothermia  
The type of procedure is a risk factor. Certain procedures are associated with a 
higher risk of wound contamination than others. The National Research Council 
(NRC) of National Academy of science was the first group to devise a 
classification system based on the estimated degree of bacterial contamination 
and demonstrated a direct relationship between the risk of infection and the 
degree of contamination. This classification is useful in estimating the risk of SSI, 
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predicting the potential pathogens and determining the need of antimicrobial 
prophylaxis. It divides wounds into 4 classes namely 
1. Clean/ class I wounds 
2. Clean-contaminated/ class II wounds 
3. Contaminated/class III wounds 
4. Dirty wounds 
Classification Criteria 
Clean  
Elective, not emergency,  
Non-traumatic,  
Primarily closed;  
No acute inflammation; 
No break in technique;  
Respiratory, Gastrointestinal, Biliary and Genitourinary 
tracts not entered.  
Clean-
contaminated  
Urgent or emergency case that is otherwise clean;  
Elective opening of respiratory, gastrointestinal, biliary 
or genitourinary tract with minimal spillage 
Not encountering infected urine or bile;  
Minor technique break.  
Contaminated  
Non-purulent inflammation;  
Gross spillage from gastrointestinal tract;  
Entry into biliary or genitourinary tract in the presence 
of infected bile or urine;  
Major break in technique;  
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Penetrating trauma <4 hours old;  
Chronic open wounds to be grafted or covered.  
Dirty  
Purulent inflammation (e.g. abscess);  
Preoperative perforation of respiratory, gastrointestinal, 
biliary or genitourinary tract;  
Penetrating trauma >4 hours old.  
 
DEFINITION AND CLASSIFICATION 
The most widely recognized definition of infection, which is used 
throughout the United States and Europe, is that devised and adopted by the 
Centres for Disease Control and Prevention. An SSI is defined as an infection 
occurring within 30 days of surgery that meets the following criteria: (1) the 
diagnosis consists of the infection of an anatomic plane by one of the following 
manifestations: collection, inflammatory signs (pain, edema, tenderness, and 
redness), dehiscence, or positive culture. SSIs are classified into incisional SSIs, 
which can be superficial or deep, and organ/space SSIs, which affect the rest of 
the body other than the body wall layers. These classifications are defined as 
follows: 
 Superficial incisional SSI - Infection involves only skin and subcutaneous 
tissue of incision  
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 Deep incisional SSI - Infection involves deep tissues, such as fascial and 
muscle layers; this also includes infection involving both superficial and 
deep incision sites and organ/space SSI draining through incision  
 Organ/space SSI - Infection involves any part of the anatomy in organs and 
spaces other than the incision, which was opened or manipulated during 
operation  
 
FIGURE 1: CLASSIFICATION OF SURGICAL SITE INFECTIONS 
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Superficial incisional SSI is more common than deep incisional SSI and 
organ/space SSI. Superficial incisional SSI accounts for more than half of all SSIs 
for all categories of surgery. The postoperative length of stay is longer for patients 
with SSI, even when adjusted for other factors influencing length of stay. 
 
 
 
CRITERIA FOR DEFINING A SURGICAL SITE INFECTION 
SUPERFICIAL INCISIONAL SSI 
 
FIGURE 2: SUPERFICIAL SURGICAL SITE INFECTION 
 Infection occurs within 30 days after the operation 
34 
 
 infection involves only skin or subcutaneous tissue of the incision  
 and at least one of the following: 
1. Purulent drainage, with or without laboratory confirmation, from the 
superficial incision. 
2. Organisms isolated from an aseptically obtained culture of fluid or tissue from 
the superficial incision. 
3. At least one of the following signs or symptoms of acute inflammation: pain 
or tenderness, localized swelling, redness, or heat and superficial incision is 
deliberately opened by surgeon, unless incision is culture-negative. 
4. Diagnosis of superficial incisional SSI by the surgeon or attending physician. 
Do not report the following conditions as SSI: 
1. Stitch abscess (minimal inflammation and discharge confined to the points 
of suture penetration). 
2. Infection of an episiotomy or new-born circumcision site. 
3. Infected burn wound. 
4. Incisional SSI that extends into the fascial and muscle layers 
DEEP INCISIONAL SSI 
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FIGURE 3: DEEP SURGICAL SITE INFECTION 
 Infection occurs within 30 days after the operation if no implant† is left in 
place or within 1 year if implant is in place and the infection appears to be 
related to the operation 
 infection involves deep soft tissues (e.g., fascial and muscle layers) of the 
incision and at least one of the following: 
1. Purulent drainage from the deep incision but not from the organ/space 
component of the surgical site. 
2. A deep incision spontaneously dehisces or is deliberately opened by a surgeon 
when the patient has at least one of the following signs of symptoms: fever 
(>38ºC), localized pain, or tenderness, unless site is culture-negative. 
3. An abscess or other evidence of infection involving the deep incision is found 
on direct examination, during reoperation, or by histopathologic or radiologic 
examination. 
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4. Diagnosis of a deep incisional SSI by a surgeon or attending physician. 
ORGAN/SPACE SSI 
 Infection occurs within 30 days after the operation if no implant is left in 
place or within 1 year if implant is in place and the infection appears to be 
related to the operation 
 Infection  involves any part of the anatomy (e.g., organs or spaces), other 
than the incision, which was opened or manipulated during an operation 
 and at least one of the following: 
1. Purulent drainage from a drain that is placed through a stab wound‡ into the 
organ/space. 
2. Organisms isolated from an aseptically obtained culture of fluid or tissue in the 
organ/space. 
3. An abscess or other evidence of infection involving the organ/space that is 
found on direct examination, during reoperation, or by histopathologic or 
radiologic examination. 
4. Diagnosis of an organ/space SSI by a surgeon or attending physician 
 
WOUND ASSESSMENT 
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No validated universal system is designed specifically to aid the 
assessment and management of surgical wounds. The most commonly used, the 
CDC definition, employs stringent criteria to classify infection. Several other 
wound scoring systems exist and two of the best are ASEPSIS and the 
Southampton Wound Assessment Scale. These enable surgical wound healing to 
be graded according to specific criteria, usually giving a numerical value, and 
therefore provide a more objective assessment of the wound. 
38 
 
 
ASEPSIS score = SUM (points from 4 daily wound inspection parameters) + 
(points for antibiotics) + (points of pus drainage) + (points for wound 
debridement) + (points for bacterial isolation) + (points for prolonged 
hospitalization) 
Interpretation: 
• Minimum score: 0            • maximum score: 70 
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ASEPSIS score Interpretation 
0 – 10 satisfactory healing 
11 – 20 disturbance of healing 
21 – 30 minor wound infection 
31 – 40 moderate wound infection 
> 40 severe wound infection 
TABLE 1: ASEPSIS SCORE GRADING 
 
 
FIGURE 4: SOUTHAMPTON WOUND GRADING 
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Southampton scale - by using the worst wound score recorded and information 
about any treatment instituted either in hospital or the community, wounds were 
regarded in four categories:  
A. normal healing;  
B. minor complication 
C. wound infection - wounds graded IV or V, or wounds treated with antibiotics 
after discharge from hospital, irrespective of the wound grading given to them by 
the nurse;  
D. major hematoma-wound or scrotal hematomas requiring aspiration or 
evacuation. 
MANAGEMENT OF SURGICAL SITE INFECTIONS 
APPROACH CONSIDERATIONS 
Most patients with wound infections are managed in the community. 
Management usually takes the form of dressing changes to optimize healing, 
which usually is by secondary intention. 
Resultant increased hospital stay due to surgical site infection (SSI) has been 
estimated at 7-10 days, increasing hospitalization costs by 20%. Occasionally, 
further intervention in the form of wound debridement and subsequent packing 
and frequent dressing is necessary to allow healing by secondary intention. 
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In 2014, the Infectious Diseases Society of America issued the following practice 
guidelines for the management of SSIs: 
Suture removal plus incision and drainage should be performed for SSIs (strong 
recommendation, low-quality evidence)  
Adjunctive systemic antimicrobial therapy is not routinely indicated but, in 
conjunction with incision and drainage, may be beneficial for SSIs associated 
with a significant systemic response, such as erythema and induration extending 
more than 5 cm from the wound edge, temperature exceeding 38.5°C, heart rate 
higher than 110 beats/min, or white blood cell (WBC) count higher than 
12,000/µL (weak recommendation, low-quality evidence)  
A brief course of systemic antimicrobial therapy is indicated in patients with SSIs 
after clean operations on the trunk, head and neck, or extremities that also have 
systemic signs of infection (strong recommendation, low-quality evidence)  
A first-generation cephalosporin or an antistaphylococcal penicillin for 
methicillin-sensitive S aureus (MSSA)—or vancomycin, linezolid, daptomycin, 
telavancin, or ceftaroline where risk factors for methicillin-resistant S aureus 
(MRSA) are high (nasal colonization, prior MRSA infection, recent 
hospitalization, or recent antibiotics)—is recommended (strong recommendation, 
low-quality evidence)  
42 
 
Agents active against gram-negative bacteria and anaerobes, such as a 
cephalosporin or fluoroquinolone in combination with metronidazole, are 
recommended for infections after operations on the axilla, gastrointestinal tract, 
perineum, or female genital tract (strong recommendation, low-quality evidence) 
ANTIBIOTIC PROPHYLAXIS 
The use of antibiotics was a milestone in the effort to prevent wound infection. 
The concept of prophylactic antibiotics was established in the 1960s when 
experimental data established that antibiotics had to be in the circulatory system 
at a high enough dose at the time of incision to be effective.  
It is generally agreed that prophylactic antibiotics are indicated for clean-
contaminated and contaminated wounds. Antibiotics for dirty wounds are part of 
the treatment because infection is established already. Clean procedures might be 
an issue of debate. No doubt exists regarding the use of prophylactic antibiotics 
in clean procedures in which prosthetic devices are inserted; infection in these 
cases would be disastrous for the patient. However, other clean procedures (eg, 
breast surgery) may be a matter of contention.  
Criteria for the use of systemic preventive antibiotics in surgical procedures are 
as follows: 
Systemic preventive antibiotics should be used in the following cases: A high risk 
of infection is associated with the procedure (eg, colon resection); consequences 
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of infection are unusually severe (eg, total joint replacement); the patient has a 
high NNIS risk index  
The antibiotic should be administered preoperatively but as close to the time of 
the incision as is clinically practical Antibiotics should be administered before 
induction of anesthesia in most situations  
The antibiotic selected should have activity against the pathogens likely to be 
encountered in the procedure  
Postoperative administration of preventive systemic antibiotics beyond 24 hours 
has not been demonstrated to reduce the risk of SSIs.  
Qualities of prophylactic antibiotics include efficacy against predicted 
bacterial microorganisms most likely to cause infection, good tissue penetration 
to reach wound involved, cost effectiveness, and minimal disturbance to intrinsic 
body flora. 
The timing of administration is critically important because the 
concentration of the antibiotic should be at therapeutic levels at the time of 
incision, during the surgical procedure, and, ideally, for a few hours 
postoperatively. Antibiotics are administered intravenously, generally 30 minutes 
prior to incision; they should not be administered more than 2 hours prior to 
surgery. 
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Colorectal surgical prophylaxis additionally requires bowel clearance with 
enemas and oral nonabsorbable antimicrobial agents 1 hour before surgery. High-
risk cesarean surgical cases require antibiotic administration as soon as the 
clamping of the umbilical cord is completed.  
 
PERIOPERATIVE RECOMMENDATIONS 
Perioperative recommendations have been made for minimizing wound infection 
and SSI, supported by varying degrees of evidence 
PREOPERATIVE PATIENT PREPARATION 
Category IA recommendations for preoperative patient preparation include the 
following: 
Identify and treat all infections remote from the surgical site; delay operation in 
elective cases until infection is treated  
Do not remove hair unless it infringes on the surgical field; if hair removal is 
required, it should be removed immediately before operation and preferably with 
electric clippers  
Category IB recommendations include the following: 
Patients should cease tobacco consumption in any form for at least 1 month 
preoperatively  
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Optimize blood glucose level and avoid hyperglycemia  
Patients are to shower/bathe with antiseptic on at least the night before surgery  
Necessary blood products may be administered  
The category II recommendation is as follows: Provided that preoperative patient 
preparation is adequate, minimize preoperative hospital stay. 
No recommendations are made regarding the following: 
Gradual reduction/discontinuance of steroid use before elective surgery  
Enhanced nutritional intake solely to prevent SSI  
Preoperative topical antibiotic use in nares to prevent SSI  
Measures to enhance wound space oxygenation  
PREOPERATIVE CONSIDERATIONS FOR SURGICAL TEAM MEMBERS 
Category IB recommendations regarding preoperative considerations for surgical 
team members are as follows: 
Keep fingernails short; do not wear artificial nails  
Scrub hands and forearms as high as the elbows for at least 2-5 minutes with 
appropriate antiseptic  
After scrub, keep hands up with elbows flexed and away from the body; use a 
sterile towel to dry the hands and put on a sterile gown and gloves  
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Masks should be worn in the operating suite if sterile instruments are exposed 
and throughout the surgical procedure; masks should cover the mouth and nose  
The hair on the head and face is to be covered with a hood or cap  
Liquid-resistant sterile surgical gowns and sterile gloves are to be worn by 
scrubbed surgical team members  
Visibly soiled gowns are to be changed  
Shoe covers are not necessary  
Routine exclusion of personnel colonized by organisms, such as S aureus or group 
A streptococci, is not necessary unless they are specifically linked to 
dissemination of such organisms  
Personnel with skin lesions that are draining are to be excluded from duty until 
treated and the infection has resolved  
Educate and encourage surgical personnel regarding reporting illness of 
transmissible nature to supervisory and occupational health personnel  
Policies should be established concerning patient care responsibilities for 
personnel with potentially transmissible infective illnesses, to include aspects of 
work restrictions, personnel responsibility in utilizing health services, and 
declaring illness; policies also should direct the responsible person to remove 
personnel from duty, and policy should be established for clearance to resume 
work  
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Category II recommendations are as follows: 
Clean under the fingernails prior to the first scrub of the day  
Do not wear arm/hand jewelry  
No recommendations are made regarding the following: 
Nail polish  
Restriction of scrub suits to the operating theater  
Covering the scrub suits when outside the theater  
How or where to launder theater suites  
PREOPERATIVE AND POSTOPERATIVE WOUND CARE 
A category IA recommendation for preoperative and postoperative wound care is 
that asepsis is necessary in the insertion of indwelling catheters, such as 
intravascular, spinal, or epidural catheters, and subsequent infusion of drugs. 
  
ABSCESS SECONDARY TO A SUBCLAVIAN LINE.  
Category IB recommendations include the following: 
Handle tissues gently with good hemostasis, minimize foreign bodies, and 
minimize devitalized tissue and dead space  
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For class III and IV wounds, use delayed closure or leave the wound incision 
open to heal by secondary intention  
If draining of a wound is necessary, the drain exit should be via separate incision 
distant from the wound; remove the drain as soon as possible  
Primary closed incisions should be protected with a sterile dressing for 24-48 
hours  
Hands are to be washed before and after wound dressing changes/or contact  
Category II recommendations include the following: 
Use sterile technique for wound dressing change  
Educate the patient and relatives regarding wound care symptoms of SSIs and the 
need to report such problems  
Theater environment and care of instrumentation 
Category IB recommendations for the theater environment and the care of 
instrumentation include the following: 
Maintain positive-pressure ventilation of the operating suite relative to corridors 
and surrounding areas  
Maintain a minimum of 15 air changes per hour, with at least three being fresh 
air  
49 
 
Appropriate filters (as recommended by the American Institute of Architects) 
should be used for filtration of all air, whether recirculated or fresh  
Air should enter through the ceiling and exit near the floor  
Keep operating room doors closed except for necessary entry  
The use of ultraviolet lamps in the theater is not necessary as a deterrent of SSI  
Prior to subsequent procedures, visibly soiled surfaces should be cleaned with 
Environmental Protection Agency (EPA)–approved disinfectants  
After a contaminated or dirty procedure, special cleaning or closure of the 
operating suite is not necessary  
Use of tacky mats prior to entry in the operating suite is not necessary  
Sterile surgical instruments and solutes should be assembled just prior to use  
All surgical instruments should be sterilized according to guidelines; flush 
sterilization should only be used for instruments that are required for immediate 
patient use  
Category II recommendations include the following: 
Limit the number of personnel entering the operating suite.  
Orthopedic implant surgery should be performed in an ultraclean-air 
environment.  
50 
 
Wet-vacuum the floor of the operating theater at the end of day/night using an 
EPA-approved disinfectant  
SPECIAL SITUATIONS 
ELECTIVE COLON SURGERY 
Bowel surgery results in the breakdown of the protective intestinal mucous 
membrane, with release of the facultative and anaerobic bacteria that heavily 
colonize the distal small bowel and colon. Eradication of aerobes and anaerobes 
is necessary to reduce infective complications following intestinal procedures. 
Mechanical cleansing and antibiotics could achieve this. 
Mechanical cleansing can take the form of dietary restrictions; whole gut lavage 
with one of several preparations, such as 10% mannitol solution, Fleet's phospho-
soda, or polyethylene glycol, usually is performed on the day of surgical 
intervention. Enteral antibiotic regimes to eradicate intrinsic bowel flora vary, 
with oral neomycin and erythromycin being the most popular combination in the 
United States. Other combinations with neomycin include the use of 
metronidazole and tetracycline. Prophylactic parenteral antibiotics also are used 
with the above. 
INTRAVASCULAR DEVICE-RELATED INFECTIONS 
Intravascular devices are of vital use in daily hospital practice. They are used for 
the parenteral administration of fluids, blood products, nutritional fluids, and 
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medication and for access in hemodialysis; equally important is their use in the 
monitoring of critically ill patients. 
Unfortunately, because the use of these devices constitutes an invasive procedure, 
they are associated with infectious complications that could be of a local or 
systemic nature. Recommendations for prevention and treatment are available to 
limit their associated morbidity and mortality (which could be as high as 20% in 
patients with catheter-related bloodstream infections). 
In a double-blind, randomized, controlled study of 400 patients with nontunnelled 
central venous catheters, Dettenkofer et al investigated the effectiveness of the 
antiseptic octenidine dihydrochloride, used in combination with alcohol-based 
antiseptic, against infection at central venous catheter insertion sites. One group 
of patients received skin disinfection with 0.1% octenidine with 30% 1-propanol 
and 45% 2-propanol, while a control group was disinfected with 74% ethanol 
with 10% 2-propanol. 
In this study, microbial skin colonization at the catheter insertion site and positive 
microbial cultures at the catheter tip were significantly reduced in the octenidine 
group. No significant differences in catheter-associated bloodstream infections 
were found between the groups. 
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SURGICAL CARE 
Although the goal of every surgeon is to prevent wound infections, they will arise. 
Treatment is individualized to the patient, the wound, and the nature of the 
infection. The operating surgeon should be made aware of the possibility of 
infection in the wound and determine the treatment for the wound. 
Ideally, surgical care should start with meticulous detail to strategies that prevent 
the development of SSIs in the first place. Preoperatively, attention should be 
paid to factors like optimization of patient status, proper asepsis, and surgical site 
preparation. Intraoperatively, adherence to good basic surgical principles of 
minimal and fine tissue dissection, proper selection of suture materials, and 
proper wound closure is important. 
If a SSI sets in, the treatment often involves opening the wound, evacuating pus, 
and cleansing the wound. The deeper tissues are inspected for integrity and for a 
deep space infection or source. Dressing changes allow the tissues to granulate, 
and the wound heals by secondary intention over several weeks. Early/delayed 
closure of infected wounds is often associated with relapse of infection and 
wound dehiscence. 
ADDITIONAL PREVENTIVE STRATEGIES 
Evidence shows that the close regulation of blood sugar may be a major 
determinant of wound morbidity. Although investigators have vigorously 
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pursued for decades the identification of a specific innate or acquired immune 
deficiency among patients with diabetes, it may be the blood sugar that is the 
determinant of infection for these patients. 
A second issue of considerable interest is body temperature. A prospective 
randomized study demonstrated that failure to maintain intraoperative core body 
temperature within 1-1.5°C of normal increases the SSI rate by a factor of 2. It 
raises the scientific question of whether increasing core temperature during 
operations over normal temperature might in fact protect against infection. 
A third issue is oxygenation. The fresh, hemostatic surgical incision is a 
hypoxic, ischemic environment. Maintaining or increasing oxygen delivery to the 
wound by increasing the inspired oxygen concentration administered to the 
patient perioperatively has also been shown to reduce the incidence of SSIs. It is 
presumed that increased oxygen availability is a positive host factor, perhaps via 
enhanced production of oxidant products that facilitate phagocytic eradication of 
microbes. 
Cleaning the wound margins with povidone-iodine before skin closure. 
A strategy that could bear fruit for preventing SSIs in the future is the 
establishment of dedicated infection surveillance units in hospitals with the aim 
of accomplishing the following: 
Identify epidemics by common or uncommon organisms  
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Establish the correct use of prophylaxis (ie, timing, dose, duration, choice)  
Document costs, risk factors, and readmission rates  
Monitor postdischarge infections and secondary consequences  
Ensure patient safety  
A major concern is how to prevent or minimize the emergence of 
resistance. Although resistance is not a new phenomenon, the incidence has 
increased dramatically over the past two decades. The development of new drugs 
has slowed considerably and may be unable to keep pace with the continuing 
growth of pathogen resistance. 
Accordingly, effective strategies are needed to prevent the continuing 
emergence of antimicrobial resistance. These strategies include avoiding 
unnecessary antibiotic administration and increasing the effectiveness of 
prescribed antibiotics, as well as implementing improvements in infection control 
and optimizing medical practice. 
Although an SSI rate of zero may not be achievable, continued progress in 
understanding the biology of infection at the surgical site and consistent 
applications of proven methods of prevention will further reduce the frequency, 
cost, and morbidity associated with SSIs. 
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TRICLOSAN 
 
FIGURE 5: TRICLOSAN MOLECULAR STRUCTURE 
Triclosan [5-Chloro-2-(2, 4-dichlorophenoxy) phenol] is a broad-spectrum 
antibacterial agent that inhibits bacterial fatty acid synthesis at the enoyl-acyl 
carrier protein reductase (FabI) step. Resistance to triclosan in Escherichia coli is 
acquired through a missense mutation in the fabI gene that leads to the expression 
of FabI [G93V]. The specific activity and substrate affinities of FabI [G93V] are 
similar to FabI. Two different binding assays establish that triclosan dramatically 
increases the affinity of FabI for NAD+. In contrast, triclosan does not increase 
the binding of NAD+to FabI [G93V]. The x-ray crystal structure of the FabI-
NAD+-triclosan complex confirms that hydrogen bonds and hydrophobic 
interactions between triclosan and both the protein and the NAD+ cofactor 
contribute to the formation of a stable ternary complex, with the drug binding at 
the enoyl substrate site. These data show that the formation of a noncovalent “bi-
substrate” complex accounts for the effectiveness of triclosan as a FabI inhibitor 
and illustrates that mutations in the FabI active site that interfere with the 
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formation of a stable FabI-NAD+-triclosan ternary complex acquire resistance to 
the drug.  
The fatty acid synthase system of Escherichia coli is the paradigm for the 
type II or dissociated fatty acid synthase systems. Distinct genes encode each of 
the individual enzymes, and the same basic chemical reaction is often catalyzed 
by multiple isozymes. There are four basic reactions that constitute a single round 
of elongation. The first step is the condensation of malonyl-ACP1with either 
acetyl-CoA to initiate fatty acid synthesis (FabH) or with the growing acyl chain 
to continue cycles of elongation (FabB or FabF). The β-ketoacyl-ACP is reduced 
by an NADPH-dependent β-ketoacyl-ACP reductase (FabG). Only a single 
enzyme is responsible for this step. There are two β-hydroxyacyl-ACP 
dehydrases (FabA and FabZ) capable of forming trans-2-enoyl-ACP. The 
product of the fabA gene is specifically involved in the introduction of a cis 
double bond into the growing acyl chain at the β-hydroxydecanoyl-ACP step and 
most efficiently catalyzes dehydration of short-chain β-hydroxyacyl-ACPs, 
whereas the FabZ dehydratase has a broader substrate specificity. The last 
reaction in each elongation cycle is catalyzed by enoyl-ACP reductase (FabI). 
Contrary to the initial conclusion that there were two enoyl-ACP reductases, 
based on assays in crude extracts, E. coli cells possess only a single NADH-
dependent enoyl-ACP reductases encoded by the fabI gene that utilizes all chain 
lengths.  
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The importance of fatty acid biosynthesis to cell growth and function 
makes this pathway an attractive target for the development of antibacterial 
agents. Two important control points in the cycle are the condensing enzymes 
and the enoyl-ACP reductase, and both reactions are targeted by compounds that 
effectively inhibit fatty acid synthesis. Two natural products, cerulenin and 
thiolactomycin, are potent antibiotics that function by specifically inhibiting the 
condensing enzyme reactions. The diazaborines, a class of heterocyclic 
antibacterials, inhibit fatty acid biosynthesis by blocking the FabI step. Resistance 
to the diazaborines arises from a missense mutation in the fabIgene that leads to 
the expression of a FabI [G93S] mutant protein. Similarly, the fabI analog in 
Mycobacterium tuberculosis, the inhA gene, encodes a cellular target for 
isoniazid and ethionamide. A point mutation in the inhAgene confers resistance 
to the drugs. Both isoniazid and diazaborine bind at the substrate site of the 
respective enoyl-ACP reductases and covalently react with NAD+ to form tight 
binding bi-substrate complexes. Triclosan is a broad-spectrum antibacterial agent 
that enjoys widespread applications in a multitude of contemporary consumer 
products including, soaps, detergents, toothpastes, skin care products, cutting 
boards, and mattress pads. Triclosan is widely thought to be a nonspecific biocide 
that attacks bacterial membranes, and if triclosan does not have a discrete 
mechanism of action, the acquisition of cellular resistance is unlikely. However, 
recent work reveals that resistant E. coli strains arise from missense mutations in 
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the fabIgene and that triclosan and other 2-hydroxydiphenyl ethers directly inhibit 
fatty acid biosynthesis in vivo and FabI catalysis in vitro. 
SAFETY 
Triclosan passively dissipates from implanted sutures to the surrounding 
tissues where it is absorbed into the bloodstream and widely distributed, but not 
confined to any particular tissue or organ system. Triclosan is rapidly metabolised 
in the liver principally by Phase II metabolism to glucuronide and sulphate 
conjugates with an elimination half-life of 13 hours after a single oral exposure 
(11). Therefore, triclosan is cleared from the bloodstream (over 99%) in 
approximately 3・8 days. Conjugated triclosan is readily water-soluble and is 
excreted from the body by the kidneys. There is no evidence that triclosan 
accumulates in the body over time and this pharmacokinetic profile makes it 
suitable for clinical use. 
Selected pharmacokinetic parameters after oral exposure to triclosan were 
compared between humans and hamsters to determine the usefulness of hamsters 
to simulate a human pharmacokinetic response (12). Triclosan was well-absorbed 
after oral administration in both species. The predominant metabolite was the 
glucuronide conjugate of triclosan. The elimination half-life was 11–20 hours in 
humans compared with 24–32 hours in hamsters, indicating a more rapid 
elimination of triclosan for humans. The major route of excretion was via the 
kidneys for both species. Overall, the hamster is considered to be a good surrogate 
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for humans with respect to the absorption, distribution, metabolism and 
elimination of triclosan. 
Although the pharmacokinetic studies with triclosan have been conducted 
principally after oral or topical routes of exposure (13), some intravenous studies 
in animals have been conducted to determine absolute bioavailability (14). 
Intravenous exposure by-passes the possibility of first-pass metabolism and is 
considered to represent a worst-case of what would happen after implantation of 
a suture. Comparing results for hamsters and humans, a similar pattern of 
metabolism was observed with the predominant metabolite being the glucuronide 
conjugate with free triclosan found in the urine. A similar pattern of elimination 
was also observed with >90% radiolabel being excreted in 7 days with <1% being 
found in major organs/tissues and no evidence of accumulation in the body. 
Overall, the similar metabolic pathway of triclosan after intravenous exposure 
allows for the use of the extensive safety database available after oral exposure 
to support the safety of Vicryl Plus (Ethicon, Inc., Somerville, NJ) suture.  
There is no associated experimental chronic or major adverse target organ 
toxicity, carcinogenicity, or potential for mutagenic, clastogenic or teratogenic 
effects and no adverse effects on male or female fertility, or endocrine function 
.World-wide topical exposure to triclosan-containing personal care products 
indicates that the sensitisation potential of triclosan is low. 
• 
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 Assessment of patient exposure 
Maximal single-day patient exposure to triclosan has been determined by 
using the in vivo dissipation rate from sutures to calculate margins of safety for 
systemic toxicity. For triclosan coated (Vicryl Plus) suture, 69% of the total 
triclosan content dissipates in the first 24 hours after implantation, with 99% 
dissipation by 36 days. Monocryl Plus (coated) and PDS Plus (impregnated) have 
their own dissipation profiles (15). 
• Potential for systemic toxicity 
Assuming the intra-operative, ‘worst-case’ use of 5 m of a 2–0 suture with 
472 μg triclosan/m for Vicryl Plus and 2360 μg/m for Monocryl Plus and PDS 
Plus, and considering the specific dissipation profile of triclosan from each suture, 
the maximal single-day exposure to triclosan was calculated to be 0・03, 0・08 
and 0・09 mg/kg body weight, respectively. Margins of safety, calculated by 
dividing the No-Observed-Effect-Levels from systemic toxicity studies by the 
maximal single-day exposure, range from 140 to 2500 (Tables 2 and 3) (16). 
Margins of safety of 100 are considered sufficient to ensure the safety of many 
substances. When compared to the widespread use of triclosan-containing oral 
and topical personal care products, the contribution of a maximal single daily 
exposure to triclosan from Vicryl Plus is only 12% of daily background exposure. 
Similarly, a maximal single daily exposure to triclosan from Monocryl Plus and 
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PDS Plus is 33% and 37%, respectively, compared to daily exposure from 
combined personal care products. 
• Local irritant potential 
Clinically relevant intradermal injections of Plus sutures result in a 
negligible irritant response. Studies of intramuscularly implanted Plus sutures 
showed that the tissue reaction, absorption profile and impact on wound healing 
at the implantation site were comparable to that observed for control sutures not 
containing triclosan. 
• Impact on wound healing 
Segments of Plus sutures placed in experimental incisional skin wounds 
caused no adverse cosmetic effects or changes in multiaxial biomechanical 
wound strength over time. 
Aside of multiple clinical studies discussed later, which did not report any 
interaction with wound healing; only one randomised prospective pilot study (16) 
reported that triclosan-coated sutures seem to have adverse effects on wound 
healing. The authors investigated the effect of a triclosan-coated suture on wound 
healing in 26 women undergoing a breast reduction in comparison to a similar 
suture without triclosan-coating. The main outcome measure was the incidence 
of wound dehiscence. In breasts operated on with triclosan-sutures, there was a 
wound dehiscence in 16 cases, whereas in the control group without triclosan 
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dehiscence only occurred in seven cases (P = 0・023). The authors explained the 
difference in the two groups by formation of chloroform and other chlorinated 
daughter products as a reaction of triclosan with free chlorine interacting with 
wound healing. 
However, the required amount of free chlorine, optimum pH, temperature 
and ultra violet radiation required for this reaction, are not present in the post-
surgical scar tissue and patients’ subcutaneous tissue, making it difficult to 
conclude that triclosan-coated surgical sutures are a cause for wound dehiscence. 
• Impact on reduction of infection 
 
 
FIGURE 6: Bacterial colonies (dark red) are visible in all areas of a petri dish 
except for the "zone of inhibition" around an Antibacterial Suture 
63 
 
 
Treating sutures with triclosan provides an effective strategy for reducing 
SSIs because bacterial contamination of suture material within a surgical wound 
may increase the virulence of a SSI (17). Numerous studies have confirmed the 
utility of these sutures in decreasing both bacterial colonisation of sutures and 
wound infections after surgery (18). 
TRICLOSAN AND THE RISK OF RESISTANCE 
Bacteria have evolved to survive natural and man-made stresses but there 
is no evidence of adverse effects of resistance caused by triclosan in the 
environment, even after long-term exposure (19). Therefore, there is apparently 
a disparity between what can be shown in laboratory studies and what happens in 
the real world environment for this molecule. For example, the oral cavity 
represents an environment that may be commonly exposed to triclosan but 
triclosan has been safely used in dental hygiene for some 40 years without 
evidence of dysbiosis, resistance or cross-resistance. 
The same terminology of ‘resistance’ is frequently used for antiseptics and 
antibiotics, often incorrectly. The term insusceptibility normally refers to 
resistance because of innate physiological properties of a bacterium: for example, 
many ‘environmental’ bacteria are not susceptible to a wide range of 
antimicrobials, including antiseptics, antibiotics and disinfectants. Resistance is 
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a clinical term which describes a change in susceptibility that may result in failure 
of a treatment with an antibiotic. 
Antiseptics are in many respects distinct from antibiotics. They were 
described by Hippocrates and the ancient Egyptians, and have been in widespread 
clinical use for the last 50–100 years. Insusceptibility has been noted to some 
antiseptics and is based on alterations in bacterial physiology (bacterial cell walls, 
membrane proteins and efflux pumps, cytoplasmic organelles and cell respiratory 
processes, enzymes and nucleic acid) that may or may not be reversible. 
However, smaller changes in susceptibility have also been noted to a wide variety 
of antiseptics and can be reproduced in the laboratory for some combinations of 
bacteria and antiseptics. The occurrence and implications of antibiotic resistance 
are well known, but less so for antiseptics. 
Changes in susceptibly can be shown in the laboratory to some agents, 
including triclosan, but this is not universal to all organisms and to date this has 
not been shown clinically, or environmentally, for triclosan. Cross-resistance 
(where exposure to an antiseptic causes antibiotic resistance) has also not been 
conclusively showed for triclosan in the clinical, or other environments. The 
widely accepted and unambiguous cause of antibiotic resistance is the use and 
misuse of antibiotics. Antibiotics often have a single or limited number of 
pharmacological targets in microorganisms, whereas antiseptics generally have 
multiple targets, depending on concentration. Antiseptics have a long history of 
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use, with early examples being Semmelweis’ chlorinated lime solutions (1848) 
and Lister’s carbolic spray (1869). True antiseptic ‘resistance’ is not frequently 
encountered and outcome altering changes in susceptibility are uncommon. 
Antibiotic resistance is defined as a change from a susceptible phenotype 
to a less susceptible phenotype which results in clinical, therapeutic failure. In the 
case of antiseptics, since commonly 100 times higher concentrations of antiseptic 
are used than is needed, a fourfold decrease in bacterial susceptibility will not 
result in therapeutic failure and is therefore not resistance in the true sense of the 
word. The number of cellular mechanisms, disrupted by antiseptics, increases 
with increasing concentration and, at the high concentrations used in practice to 
achieve rapid micro biocidal action, antiseptics generally produce many 
potentially lethal effects on the bacterium, such as disruption of the cell 
membrane or inactivation of a enzymes, dissipation of transmembrane ion 
gradients, etc. At lower, growth inhibiting concentrations they may act in the 
same way as antibiotics, specifically affecting one or two cellular targets. 
However, even for antiseptics that affect multiple targets, the susceptibility of 
each target is likely to be variable and dependent on the concentration of the 
antiseptic (20). 
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TABLE 2: ANTIBIOTIC SPECTRUM OF TRICLOSAN 
TRICLOSAN COATED SUTURES 
 
FIGURE 7: TRICLOSAN COATED SUTURE 
Suture material is known to be a potential agent of infection [21). To 
prevent microbial colonization of suture material in operative wounds, Triclosan-
coated polyglactin 910 suture materials with antibacterial activity (Vicryl Plus 
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and Monocryl plus Ethicon GmbH, Nordersdedt, Germany) have been developed. 
Triclosan (TC) is a broad-spectrum phenol family antiseptic, used for more than 
30 years as a safe and effective antimicrobial agent [22], against the most 
common pathogen agents that cause SSI: S. aureus and S. epidermidis. The 
antimicrobial efficacy of this material in reducing both bacterial adherence to the 
suture and microbial viability have been proven in vitro [23, 24] and in animal 
models [25–26]. Coated sutures with TC were compared clinically to no 
impregnated suture material in extragynecological surgery, and were shown to 
perform as well or better than traditional sutures with respect to intraoperative 
handling and wound healing in pediatric general surgery, pediatric neurosurgery, 
thoracic, and abdominal surgery. However, other studies suggest that TC-coated 
sutures could be inefficient or might have potential adverse effects as wound 
dehiscence, and should be used with caution [27, 28]. 
A study by Edmiston CE, SeabrookGR et al titled “Bacterial adherence to 
surgical sutures: Can antibacterial coated sutures reduce microbial 
contamination?” published in J Am Coll Surg 2006 proved that treating 
polyglactin910 with triclosan was an effective strategy in decreasing SSI by 
proving decreased adherence of both Gram positive and Gram negative bacteria 
to Triclosan coated suture material. 
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The addition of Triclosan to polyglactin910 suture does not affect the 
physical handling properties or performance characteristics like the ease of 
passage through tissues, first throw knot holding, knot security and so on. [39]  
Finally, and most importantly, the significant decrease in wound infection 
rates in patients in whom coated polyglactin910 with triclosan was used in closure 
of abdominal wounds was demonstrated by Justinger C, MoussavianMR, 
SchleveterC et al and published in Surgery-antibacterial coating of abdominal 
closure sutures and wound infection 2009.[40] 
 The use of triclosan +coated polyglactin910 in subcutaneous closure, by 
inhibiting bacterial colonization of the suture decreased pain, which can be used 
as an indicator of subclinical infection was proven in a study conducted by 
FordHR, JonesP, GainesB, ReblockH et al and published in Surg Infections 
(Larchmt) 2005-Intra-operative handling and wound healing: controlled clinical 
trial comparing coated polyglactin910 with triclosan with coated polyglactin910 
suture. [41] 
        Another study done to appraise the efficacy of coated Vicryl plus 
Antibacterial suture (coated polyglactin 910 with Triclosan) in two animal 
models of general surgery studied the inflammatory and wound healing 
processes. The results concluded that the antiseptic coated sutures normalize the 
wound healing process and had an anti-inflammatory effect. [42] 
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         A prospective, randomized, double- blinded controlled multicenter study 
was done to evaluate the impact of using triclosan- antibacterial sutures on 
incidence of surgical site infection. It was observed the incidence of surgical site 
infection was 7% in the study group compared to 15% in the control group and 
hence concluded that use of triclosan – coated polyglactin 910 antimicrobial 
suture lead to reduction of surgical site infection. [43] 
A study by Ming ET all showed that Poliglecaprone 25 suture with 
triclosan inhibited bacterial colonization of the suture compared with untreated 
suture after direct in vivo challenge with S. aureus and E. coli in animal models. 
[44] 
Another study revealed that Triclosan reduced in vitro colonization of 
poliglecaprone 25 suture by several strains of bacteria compared with untreated 
control sutures. [45]  
A study showed that The in vitro model demonstrated a considerable 
reduction (p < 0.01) in Gram-positive and Gram-negative bacterial adherence to 
a triclosan-coated braided suture, which was associated with decreased microbial 
viability (p < 0.001). Because bacterial contamination of suture material within a 
surgical wound may increase the virulence of a surgical site infection, treating the 
suture with triclosan provides an effective strategy for reducing perioperative 
surgical morbidity. [46]  
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Studies have shown use of these suture (monocryl plus) in decreasing both 
bacterial colonisation of suture and infections after surgery. Many studies support 
the hypothesis that triclosan can reduce the risk of suture-associated surgical site 
infections. [47]  
A recent single centre prospective double blinded randomised control 
trial21done in the United States of America looked at the use of triclosan coated 
sutures (polyglactin 910) inclosure of galea and fascia in cerebrospinal fluid 
shunts surgery and infection rates. The results were: the incidence of infection in 
the study group was 2(4.3%) of 46 while in the control 8(21%) of 38. The study 
was halted prematurely by the researchers after they realised significantly higher 
infection rates in the control group. The conclusion drawn from that study was 
that antimicrobial sutures was associated with a reduced risk of postoperative 
shunt infection, however the study was terminated prematurely at 6 months and 
it recommended further studies be done to confirm this association.[48] 
 A double blinded randomised control trial done in Thammasat university 
Thailand, evaluated the efficacy and safety of vicryl plus compared to vicryl in 
reducing surgical site infection in appendectomy operation. In the study either 
vicryl plus or vicryl was used to close the abdominal sheath and the patients were 
followed up for one year. The preliminary results showed that there was no 
statistical difference in the surgical site infection between vicryl and vicryl plus 
(8 and 10%, p= 0.05). [49]     
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In another study done in Japan looked at the use of triclosan coated sutures 
in colorectal surgery. All the patients received intravenous antibiotics pre and 
post operatively. In the study they also included patients with diabetes mellitus, 
smokers and on steroids. The infection rate was 4.3% for the vicryl plus group 
while 9.3% for the control. There was a statistically significant difference in the 
two groups. The conclusion from the study was that triclosan coated sutures can 
reduce the incidence of wound infection in colorectal surgery. [50] 
 We believe that this study presented an achievement by confirming that 
the use of triclosan-coated sutures (Vicryl Plus) in midline laparotomy can reduce 
SSIs. Triclosan-coated sutures may be one of the most effective antimicrobial 
agents developed to date and they are expected to greatly contribute to decreasing 
SSIs if combined with refined and aseptic surgery Techniques and the proper use 
of prophylactic antibiotics. SSI rates using triclosan-coated sutures were greatly 
decreased to 1.39% in gastric cancer patients, compared with the historical data. 
[51] 
SRC rates were 13% and 8%, respectively, for Group 1 and Group 2, which 
is consistent with most studies (0.8–45%) [29–31]. The observed complication 
rate for patients treated with TC-coated suture material seemed to be similar to 
that observed during the first study period (Table 2) and may be wrongly 
interpreted as unsatisfactory. However, based on patient and surgery 
characteristics, the complication rate was expected to be higher. This was shown 
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through the use of a model that was based and validated on the classical 
population. [52] 
 
In the control group, 75 patients (12.2%) developed wound infections. In 
the study group, 31 patients (6.6%) developed wound infections, which was 
significantly lower. Emergency cases; laparoscopic cases, including some 
cholecystectomy and colectomy cases; American Society of Anaesthesiologists 
classification; the use of immunosuppressive therapy; colostomy cases; wound 
classification; and suture material were identified as the risk factors for wound 
infections. In both groups, as the wound classification worsened, the wound 
infection rate increased. Triclosan-coated polyglactin 910 antimicrobial sutures 
lead to a significant decrease in the incidence of surgical site infections, especially 
in clean/contaminated cases. [53] 
When a PDS loop suture for abdominal wall closure was used, 42 (11.3%) 
patients with wound infections were detected. The number of patients with 
wound infections decreased significantly to 31 when the PDS plus for 
abdominal wall closure was used (6.4%, P <.05). Other risk factors for the 
development of side infections were comparably in the two groups. This clinical 
pathway facilitated trial shows that triclosan impregnation of a 2-0 
polydioxanone closing suture can decrease wound infections in patients having 
a laparotomy for general and abdominal vascular procedures. [54]  
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The updated SLR included 15 RCTs with 4,800 patients. No publication 
bias was suggested in the analysis. The predominant effect estimated a relative 
risk of 0.67 (95% CI: 0.54–0.84, p = 0.00053) with an overall lower frequency of 
SSI in the TS arm than in the NTS arm. Results were robust to sensitivity analysis. 
The two additional peer-reviewed double-blind RCTs of this update confirmed 
the predominant effect found in the authors’ previous meta-analysis and 
established the robustness of conclusions that were lacking previously. This SLR 
and meta-analysis showed that the use of triclosan antimicrobial sutures reduced 
the incidence of SSI after clean, clean-contaminated, and contaminated surgery. 
The two additional peer reviewed double blind RCTs reinforced the evidence 
level of this SLR. [55] 
Nakamura and colleagues2 investigated 410 patients undergoing open and 
laparoscopic colorectal surgery and showed a non-significant benefit for coated 
sutures, although a slightly greater reduction in SSI was reported for patients who 
had open surgery. This non-significant benefit supports Fujita’s underlying 
hypothesis that triclosan-coated are better than uncoated sutures in special high-
risk groups, such as in potential wound contamination after open colorectal 
surgery. [56] 
Seven randomized, controlled trials evaluating 1631 patients were 
retrieved from electronic databases. There were 760 patients in the ABS group 
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and 871 patients in the simple suture group. There was moderate heterogeneity 
among trials (Tau2= 0.12; chi2= 8.40, df = 6 [P<0.01]; I2= 29%). Therefore in 
the random-effects model, the use of ABS for skin closure in surgical patients 
was associated with a reduced risk of developing surgical site infections (OR, 
0.16; 95% CI, 0.37, 0.99; z = 2.02; P<0.04) and postoperative complications (OR, 
0.56; 95% CI, 0.32, 0.98 z = 2.04; P=0.04). The durations of operation and lengths 
of hospital stay were similar following the use of ABS and SS for skin closure in 
patients undergoing various surgical procedures.  Use of ABS for skin closure in 
surgical patients is effective in reducing the risk of surgical site infection and 
postoperative complications. ABS is comparable with SS in terms of length of 
hospital stay and duration of operation. [57] 
Scores for intraoperative handling were favourable and not significantly 
different for both sutures, although coated polyglactin 910 suture with triclosan 
received more "excellent" scores (71% vs. 59%). Wound healing characteristics 
were comparable for both sutures except for pain on postoperative day 1. 
Significantly fewer patients treated with polyglactin 910 suture with triclosan 
reported pain on day 1 than patients who received the other suture (68% vs. 89%, 
p = 0.01). The overall incidence of adverse events was 18%; none was device 
related. Coated polyglactin 910 suture with triclosan performed as well or better 
than traditional coated polyglactin 910 suture in paediatric patients undergoing 
general surgical procedures. The incidence of postoperative pain was 
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significantly less in patients treated with coated polyglactin 910 suture with 
triclosan than the traditional suture. We speculate that polyglactin 910 suture with 
triclosan, by inhibiting bacterial colonization of the suture, reduced pain that can 
be an indicator of "subclinical" infection. Coated polyglactin 910 suture with 
triclosan may be a useful alternative in patients at increased risk of developing 
SSI. [58] 
The scores for surgeons' evaluation of suture material were favourable 
and similar for both sutures. Surgeons could not reliably make a distinction in 
handling between the two sutures. Breaking strength retention was the same for 
both sutures, ranging from 79% on day 14 to 5% on day 35. Both sutures were 
essentially absorbed at 70 days post-implantation. Product characterization 
assessment of the two sutures found them to be indistinguishable. The addition 
of triclosan to coated polyglactin 910 sutures did not affect physical handling 
properties or performance characteristics based on the testing and evaluations 
performed. [59] 
The oral LD (50) values for triclosan ranged from 3,750 to 5,000 mg/kg, 
whereas the LD (50) after subcutaneous injection was >14,600 mg/kg. Safety 
factors calculated from repeated daily dosing studies ranged from 1,000 to 25,000 
times the no-observed-effect levels. There was no evidence of carcinogenic 
potential in either species, and genotoxicity studies were negative. Reproductive 
toxicity studies did not reveal any evidence of teratogenic potential. There was 
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no evidence of skin sensitization potential in controlled studies. Pharmacokinetic 
studies in animals and humans have shown that triclosan is rapidly absorbed, well 
distributed in the body, metabolized in the liver, and excreted by the kidneys, with 
no indication of accumulation over time. Biocompatibility studies showed that 
coated polyglactin 910 suture with triclosan was non-cytotoxic, non-irritating, 
and not a chemical pyrogen. In addition, an intramuscular implantation study 
demonstrated a tissue reaction, a healing response, and an absorption profile 
comparable to current polyglactin 910 suture. The extensive toxicology database 
supporting the safety of triclosan and the biocompatibility studies conducted on 
coated polyglactin 910 suture with triclosan demonstrate the safety of this suture 
for clinical use. Considering the clinical relevance of surgical site infections and 
the relatively low level of triclosan required to inhibit bacterial colonization of 
the suture, the use of this antimicrobial technology is well suited to this 
application. [60] 
A systematic search of both randomized (RCTs) and nonrandomized (non-
RCT) studies was performed on PubMed Medline, OVID, EMBASE, and 
SCOPUS, without restrictions in language and publication type. Random-effects 
models were utilized and pooled estimates were reported as the relative risk (RR) 
ratio with 95% confidence interval (CI). Tests for heterogeneity as well as meta-
regression, subgroup, and sensitivity analyses were performed. 
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A meta analysis study included a total of 29 studies (22 RCTs, 7 non-
RCTs). The overall RR of acquiring an SSI was 0.65 (95% CI: 0.55–0.77; 
I2=42.4%, P=.01) in favor of TCS use. The pooled RR was particularly lower for 
the abdominal surgery group (RR: 0.56; 95% CI: 0.41–0.77) and was robust to 
sensitivity analysis. Meta-regression analysis revealed that study design, in part, 
may explain heterogeneity (P=.03). The pooled RR subgroup meta-analyses for 
randomized controlled trials (RCTs) and non-RCTs were 0.74 (95% CI: 0.61–
0.89) and 0.53 (95% CI: 0.42–0.66), respectively, both of which favored the use 
of TCSs. They came to a conclusion that Triclosan coated sutures reduced the 
risk of SSI by 26% among patients undergoing surgery. This effect was 
particularly evident among those who underwent abdominal surgery. [61] 
Thirteen randomized clinical trials involving 5256 participants were 
included. Triclosan-coated sutures were associated with lower risk of SSI than 
uncoated sutures across all surgeries (risk ratio [RR] 0.76, 95% confidence 
interval [CI] 0.65-0.88, P < 0.001). Similar proportions of patients experienced 
wound dehiscence with either type of suture (RR 0.97, 95% CI 0.49-1.89, P = 
0.92). Subgroup analysis showed lower risk of SSI with triclosan-coated sutures 
in abdominal surgeries (RR 0.70, 95% CI 0.50-0.99, P = 0.04) and group with 
prophylactic antibiotic (RR 0.79, 95% CI 0.63-0.99, P = 0.04). However, such 
risk reduction was not observed in cardiac surgeries, breast surgeries, or group 
without prophylactic antibiotic. They concluded that Triclosan-coated sutures can 
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decrease the incidence of SSI in abdominal surgeries and might not interfere with 
wound healing process. Nevertheless, further studies are needed to examine 
whether triclosan-coated sutures are effective at preventing SSI in non-abdominal 
surgeries and to further study the interaction of antibiotic prophylaxis with 
triclosan-coated sutures. [62] 
In a study titled Triclosan-coated sutures for the reduction of sternal wound 
infections? A retrospective observational analysis by Stefan Stadler and Tatjana 
Fleck, the rate of sternal wound infection was 3.0% in the conventionally closed 
group, 2.3% in the group with only the sternal fascia closed using triclosan 
sutures, and 3.2% in the group with total triclosan suture closure (fascia, 
subcutaneous tissue and skin). They came to a conclusion that Triclosan-coated 
sutures therefore showed no advantage in avoiding or reducing sternal wound 
infections. As the cost of these new materials is higher, the rationale for using 
these sutures remains to be determined. 
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OBSERVATION AND RESULT 
STATISTICAL ANALYSIS AND INTERPRETATIONS:  
 The study subjects were described according to the type variables. The 
continuous variables were described by averages and the categorical variables 
were described by percentages. The descriptions of continuous variables were 
interpreted by student “t” tests and the descriptions of categorical variables were 
interpreted by χ2 tests of goodness of fits. The relationships were analysed and 
interpreted by χ2 tests of independence. The above statistical procedures were 
performed with the help of the statistical packages namely IBM SPSS statistics-
20. The P- values less than or equal to 0.05 (P<0.05) were treated as statistically 
significant. 
RESULTS: 
DESCRIPTION OF THE STUDY SUBJECTS:  
 The study subjects namely abdominal surgical cases were described 
according to their age and gender, type of diagnosis and surgical procedure 
performed. 
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Table-1: Percentage distribution of gender wise age group:  
Age group 
(years) 
Male Female Total 
Frequency % Frequency % Frequency % 
<20 2 2.9 0 0.0 2 2.9 
20-39 20 28.6 5 7.1 25 35.7 
40-59 18 25.7 7 10.0 25 35.7 
60+ 15 21.4 3 4.3 18 25.7 
Total 55 78.6 15 21.4 70 100.0 
  
 
The above table-1 states the age distribution according to the gender of the 
subjects. The males were 78.6% and females were 21.4%. The mean age of the 
males was 44.8 ±17.6 and females were 50.1±14.2 years. The difference between 
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the mean ages were not statistically significant (p>0.05). The total subjects mean 
age was 45.9±17.0 years with a range of 18-86 years.  
 
Table-3: Percentage distribution of Diagnosis. 
Sl. No Diagnosis Frequency Percentage 
1 Appendicular  abscess 1 1.4 
2 Colonic perforation 2 2.9 
3 Gastric perforation 2 2.9 
4 Ileal perforation 5 7.1 
5 Intestinal obstruction 25 35.7 
6 Jejunal perforation 1 1.4 
7 Liver laceration 3 4.3 
8 Obstructed hernia 5 7.1 
9 Perforative peritonitis 23 32.9 
10 Retroperitoneal hematoma 1 1.4 
Total 70 100.0 
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The diagnosis of study subjects were posted in the above table-3. The 
Intestinal obstruction was the major (35.7%) diagnosis and next was the 
Perforative peritonitis (32.7%). Both of Appendicle abscess (1.4%) and 
retroperitoneal hematoma (1.4%) was the least diagnosed symptoms.  
 
Table-4: Percentage distribution of Procedures: 
Sl. No Procedures Frequency Percentage 
1 Adhesiolysis 10 14.3 
2 Colostomy 5 7.1 
3 Gastrojejunostomy 1 1.4 
4 Ileostomy 1 1.4 
Appendicul
ar  abscess
Colonic
perforation
Gastric
perforation
Ileal
perforation
Intestinal
obstruction
Jejunal
perforation
Liver
laceration
Obstructed
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Perforative
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Retroperito
neal
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Frequency 1 2 2 5 25 1 3 5 23 1
Percentage 1.4 2.9 2.9 7.1 35.7 1.4 4.3 7.1 32.9 1.4
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5 Lavage and drainage 6 8.6 
6 Obstruction release 1 1.4 
7 Omental patch 23 32.9 
8 Primary closure 6 8.6 
9 Resection anastomosis 17 24.3 
Total 70 100.0 
 
The table-4 states the procedures adopted among the study subjects. The 
Omental patch (32.9%) was the leading procedures of the subjects. The 24.3% 
persons had undergone the procedure Resection anastomosis as second most 
procedures. The Gastrojejunostomy, Ileostomy and Obstruction release were the 
least scored procedure with 1.4% each. The differences between them were 
statistically very highly significant (P<0.001). 
 
Table-5: Percentage distribution of Diabetics: 
Sl. No Diabetic status Frequency Percentage 
1 Diabetic  17 24.3 
2 Non-Diabetic 53 75.7 
Total 70 100.0 
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 The above table -5 classifies the diabetic status of the study subjects as 
diabetic and non-diabetic. The diabetic subjects were 24.3% and non-diabetics 
were 75.7%. The difference was statistically very highly significant (P<0.001).  
 
Table-6: Percentage distribution of Wound class: 
Sl. No Wound Class Frequency Percentage 
1 2 16 22.9 
2 3 24 34.3 
3 4 30 42.8 
Total 70 100.0 
The type of wound was stated in the above table-6. The types 2, 3, and 4 
were 22.9%, 34.3% and 42.8% respectively. The difference between the wound 
classes was not statistically significant (P>0.05). 
 
Table-7: Association between wound class with SSI. 
Wound class 
Positive Negative Total 
No % No % No % 
2 6 8.6 10 14.3 16 22.9 
3 7 10.0 17 24.3 24 34.3 
4 10 14.3 20 28.5 30 42.8 
Total 23 32.9 47 67.1 70 100.0 
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The wound class was associated with the positive and negative of SSI. The 
wound class and SSI were not statistically significantly correlated. 
 
Relationships between abdominal closures with suture materials: 
  The relationships between wound class, 3rd day, 7th day and total suture 
infection were studied. The relationship of suture infection was associated with 
type of culture positive. 
 
Table-8: Association between the suture materials used and infections on 3rd  
              Day of surgery: 
Suture 
materials 
- + Total 
χ2 df Sig. 
No % No % No % 
V 24 34.3 10 14.3 34 48.6 
.945 1 P>0.05 V+ 29 41.4 7 10.0 36 51.4 
Total 53 75.7 17 24.3 70 100.0 
  
The association of suture materials with the outcome of infections on 3rd 
were showed in the above table-8. There was no statistically significant 
association between the suture materials with outcome of infections on the third 
day of surgery (P>0.05).   
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Table-9: Association between the suture materials used and infections on 7th   
              Day of surgery: 
Suture 
materials 
- + Total 
χ2 df Sig. 
No % No % No % 
V 28 40.0 6 8.6 34 48.6 
4.296 1 P<0.05 V+ 35 50.0 1 1.4 36 51.4 
Total 63 90.0 7 10.0 70 100.0 
  
In the above table-9, the relationship between the suture materials with the 
outcome of infections was stated on the seventh day of operations. The results 
revealed that there was statistically significant relationship between them 
(P<0.05). The positive outcome of infection (8.6%) of V was significantly 
differed with the positive outcome of infection (1.4%) of V+.  Similarly the 
negative outcome of infections (40%) was associated with V.   
 
Table-10: Association between the suture materials used and total SSI: 
Suture 
materials 
- + Total 
χ2 df Sig. 
No % No % No % 
V 19 27.1 15 21.5 34 48.6 
3.842 1 P<0.05 V+ 28 40.0 8 11.4 36 51.4 
Total 47 67.1 23 32.9 70 100.0 
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The above table-9 states the relationship between the suture materials and 
the total outcome of infections. The results revealed that there was statistically 
significant relationship between them (P<0.05). The positive outcome of 
infection (21.5%) of V was significantly differed with the positive outcome of 
infection (11.4%) of V+.  Similarly the negative outcome of infections (27.1%) 
was associated with V and negative outcome of infections (40.0%) was associated 
with V+ materials. 
   
Table-11: Percentage distribution of type of Culture positive:  
Culture 
positive 
Frequency % 
E. Coli 3 13 
Klebsiel 6 26 
No growth 5 22 
Staph 6 26 
Others 3 13 
Total 23 100 
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The above table-11 states the culture types of total SSI. Among them E.Coli was 
4.3%,  Klebsiel 8.6%, no growth 7.1%, Staph 8.6% and others 4.3%. 
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DISCUSSION 
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DISCUSSION 
Surgical site infection remains a major burden in healthcare and so it is 
imperative that more research is done to find new innovative ways of reducing it. 
The purpose of this study was to evaluate the effectiveness of antimicrobial 
coated suture vicryl plus from Ethicon (triclosan coated polyglactin 910 suture) 
in reducing superficial surgical site infection in clean wounds. 
The contaminated and dirty wound infection rate is mainly associated with 
incidene of post operative wound infections. It is for this reason that we also 
decided to study wound infection rates in the emergency setup so as to assess the 
quality of surgical care we give to our patients. From the study we found the 
infection rate for clean-contaminated wound to be 21%, which was considerably 
higher than the expected rate for clean wound which is less than 10%. For 
contaminated cases it was 33 % while the expected rate was 20%, which is also 
high. But for dirty cases the incidence was 35 % which was within the expected 
range of <40%. [8, 10] Therefore, there is certainly need to do more in prevention 
and management of SSI at our facility. 
The age of the patient was not found to be a contributing risk factor in the 
development of SSI. There was no age group associated with an increased risk of 
developing SSI (P value 0.761).  Our study population had a median age for males 
was 44.8 and females was 50.1. 
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From this study we demonstrated a reduction of superficial SSI when 
triclosan coated polyglactin 910 (vicryl plus) was used as compared to plain 
vicryl. There was a significant statistically difference (P-value <0.05) 
demonstrated between the two sutures. This is in line with some previous studies 
that also demonstrated significant difference between the two sutures. It is 
important to note that the mechanisms leading to surgical site infections are not 
fully understood, however the presence of a foreign material like a suture is 
known to lower the size of bacterial inoculi necessary to develop infection hence 
creating an antibacterial environment within the wound is supposed to reduce the 
risk of SSI,. This was the thinking behind the creation of antimicrobial coated 
suture. 
Although vicryl plus has been demonstrated to reduce SSI in some areas 
like abdominal surgery, it has not been found to be effective in others. 
One possibility is that, like all good innovations it may be overused and 
misused. The widespread use of triclosan for many years in topically personal 
hygiene products like toothpaste, soap etc. may lead to diminished antimicrobial 
activity. This inevitable can lead to the development of drug resistance, this has 
been demonstrated in some studies  
The other issue of concern is safety when using triclosan coated sutures, 
although several studies have demonstrated triclosan to be relatively safe in 
classic toxicological terms. 
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Currently in the United States, the Food and Drug Administration (FDA) 
is reviewing the safety and efficacy of triclosan. And so it would be prudent to 
exercise caution when using triclosan coated sutures. 
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CONCLUSION 
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CONCLUSION 
In conclusion since there was a definite advantage inferred to the patients 
by using triclosan coated polyglactin 910, it is the opinion of the researcher that 
triclosan coated sutures has a role to play in reducing SSI in clean-contaminated, 
contaminated and dirty wounds and its use should be confined to areas where its 
application has proven benefits. However more studies should be done to clearly 
define its role and indications in surgery. Microbialogical culture and sensitivity 
should be done, for all the patients who developed SSI so as to elucidate local 
causative agents and the most effective drugs. Microbiological testing for local 
patterns of resistance to triclosan should also be done. Prudent use of 
antimicrobial so as to reduce the development of drug resistance. 
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ANNEXURE I 
 LIST OF FIGURES  
S.NO TITLE 
1 CLASSIFICATION OF SURGICAL SITE INFECTIONS 
2 SUPERFICIAL SURGICAL SITE INFECTION 
3 DEEP SURGICAL SITE INFECTION 
4 SOUTHAMPTON WOUND GRADING 
5 TRICLOSAN MOLECULAR STRUCTURE 
6 BACTERIAL COLONIES (DARK RED) ARE VISIBLE IN ALL 
AREAS OF A PETRI DISH EXCEPT FOR THE "ZONE OF 
INHIBITION" AROUND A ANTIBACTERIAL SUTURE 
7 TRICLOSAN COATED SUTURE 
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ANNEXURE II 
PROFORMA 
1. Name: 
2. Age: 
3. Sex: 
4. Inpatient no: 
5. Comorbidities: 
6. Height: 
7. Weight: 
8. Diagnosis: 
9. Class of wound: 
10. Procedure done: 
11. Suture material used: 
12. Adverse effects: 
Adverse effect III POD VII POD 30th POD 
Purulent discharge    
Pain/tenderness    
Localised Swelling    
Redness    
Raised local temperature    
 
13. CULTURE: 
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ANNEXURE II 
CONSENT FORM 
I exercising my free power of choice, hereby give my full free and 
voluntary consent for myself to be a subject of the study “ABDOMINAL 
CLOSURE WITH ANTIBACTERIAL COATED SUTURE MATERIALS AND 
ITS RELATION TO THE INCIDENCE OF POST OPERATIVE 
SUPERFICIAL SURGICAL SITE INFECTION RATES”.  
I have been informed to my satisfaction by attending surgeon Dr. ………… 
the purpose of the study, the clinical and microbiological investigations that are 
to be carried out and the nature and consequences of the surgery, anaesthesia and 
the likely complications in my own language.  
I am aware of my right to not to opt for this study without having to give 
reasons for doing so. 
 
 
 
Signature of the surgeon:     Signature of the patient: 
Date:         Date: 
113 
 
 S.
N
O
N
A
M
E
A
G
E
SE
X
IP
. N
O
D
IA
G
N
O
SI
S
PR
O
CE
D
U
RE
D
IA
BE
TI
C
H
IV
BM
I
CL
A
SS
 O
F 
 W
O
U
N
D
SU
TU
RE
 U
SE
D
SS
I
III
 P
O
D
V
II 
PO
D
30
TH
 P
O
D
CU
LT
U
RE
1
ES
A
KK
IM
U
TH
U
38
M
11
13
1
PE
RF
O
RA
TI
V
E 
PE
RI
TO
N
IT
IS
O
M
EN
TA
L 
PA
TC
H
N
N
26
4
v
-
-
-
-
2
M
O
O
KA
M
M
A
L 
55
F
11
77
7
PE
RF
O
RA
TI
V
E 
PE
RI
TO
N
IT
IS
O
M
EN
TA
L 
PA
TC
H
N
N
32
4
v+
-
-
-
-
3
CH
EL
LA
PA
62
M
12
14
2
O
BS
TR
U
CT
ED
 H
ER
N
IA
RE
SE
CT
IO
N
 A
N
A
ST
O
M
O
SI
S
N
N
22
3
v+
+
+
-
-
st
ap
h
4
KR
IS
H
N
A
N
41
M
12
46
1
PE
RF
O
RA
TI
V
E 
PE
RI
TO
N
IT
IS
O
M
EN
TA
L 
PA
TC
H
N
N
26
4
v
-
-
-
-
5
SU
D
A
LA
IM
A
D
A
N
35
M
12
21
4
IN
TE
ST
IN
A
L 
O
BS
TR
U
CT
IO
N
RE
SE
CT
IO
N
 A
N
A
ST
O
M
O
SI
S
N
N
26
3
v+
-
-
-
-
6
G
O
M
A
TH
Y
35
F
13
07
9
IN
TE
ST
IN
A
L 
O
BS
TR
U
CT
IO
N
A
D
H
ES
IO
LY
SI
S
N
N
28
2
v
+
+
-
-
st
ap
h
7
A
BD
U
L 
N
A
FO
O
R
86
M
13
15
9
IN
TE
ST
IN
A
L 
O
BS
TR
U
CT
IO
N
A
D
H
ES
IO
LY
SI
S
Y
N
21
2
v
+
-
+
-
kl
eb
si
el
la
8
M
A
YA
N
D
I
60
M
13
57
2
ST
A
B 
IN
JU
RY
PR
IM
A
RY
 C
LO
SU
RE
Y
N
32
3
v+
-
-
-
-
9
A
KB
A
R 
A
LI
62
M
13
61
9
O
BS
TR
U
CT
ED
 H
ER
N
IA
RE
SE
CT
IO
N
 A
N
A
ST
O
M
O
SI
S
N
N
27
3
v+
+
+
-
-
e.
 c
ol
i
10
M
A
RI
30
M
13
83
5
PE
RF
O
RA
TI
V
E 
PE
RI
TO
N
IT
IS
O
M
EN
TA
L 
PA
TC
H
N
N
31
4
v+
-
-
-
-
11
TH
A
N
G
A
M
56
F
13
83
0
IN
TE
ST
IN
A
L 
O
BS
TR
U
CT
IO
N
RE
SE
CT
IO
N
 A
N
A
ST
O
M
O
SI
S
Y
N
34
3
v+
-
-
-
-
12
G
U
N
A
SE
KA
RA
N
20
M
14
82
0
ST
A
B 
IN
JU
RY
PR
IM
A
RY
 C
LO
SU
RE
N
N
29
3
v
+
-
+
-
no
 g
ro
w
th
13
M
A
H
ER
 N
IS
H
A
53
F
15
34
5
O
BS
TR
U
CT
ED
 H
ER
N
IA
O
BS
TR
U
CT
IO
N
 R
EL
EA
SE
Y
N
34
2
v+
-
-
-
-
14
SU
BR
A
M
A
N
IA
N
61
M
15
31
7
PE
RF
O
RA
TI
V
E 
PE
RI
TO
N
IT
IS
O
M
EN
TA
L 
PA
TC
H
N
N
24
4
v+
-
-
-
-
15
SU
BB
U
LA
KS
H
M
I
35
F
15
44
5
IN
TE
ST
IN
A
L 
O
BS
TR
U
CT
IO
N
A
D
H
ES
IO
LY
SI
S
N
N
32
2
v
+
+
-
-
ot
he
rs
16
M
A
H
A
RA
JA
24
M
15
54
8
PE
RF
O
RA
TI
V
E 
PE
RI
TO
N
IT
IS
O
M
EN
TA
L 
PA
TC
H
N
N
28
4
v
-
-
-
-
17
G
A
N
ES
A
N
72
M
16
21
4
PE
RF
O
RA
TI
V
E 
PE
RI
TO
N
IT
IS
O
M
EN
TA
L 
PA
TC
H
Y
N
22
4
v
-
-
-
-
18
KA
N
N
A
N
40
M
16
28
2
PE
RF
O
RA
TI
V
E 
PE
RI
TO
N
IT
IS
O
M
EN
TA
L 
PA
TC
H
N
N
29
4
v
+
+
-
-
st
ap
h
19
KA
LY
A
N
I
55
F
16
95
6
PE
RF
O
RA
TI
V
E 
PE
RI
TO
N
IT
IS
O
M
EN
TA
L 
PA
TC
H
N
N
33
4
v+
-
-
-
-
20
M
A
D
A
SA
M
Y
70
M
17
49
6
IN
TE
ST
IN
A
L 
O
BS
TR
U
CT
IO
N
CO
LO
ST
O
M
Y
N
N
21
3
v
-
-
-
-
21
BA
LA
JI
 S
H
A
N
KA
R
46
M
18
21
1
A
PP
EN
D
IC
U
LA
R 
A
BS
CE
SS
LA
V
A
G
E 
A
N
D
 D
RA
IN
A
G
E
N
N
25
4
v+
+
+
-
-
kl
eb
si
el
la
22
PO
N
 R
A
SA
TH
I
58
F
16
28
8
IN
TE
ST
IN
A
L 
O
BS
TR
U
CT
IO
N
CO
LO
ST
O
M
Y
N
N
32
3
v+
-
-
-
-
23
RA
D
H
A
70
M
18
72
5
IN
TE
ST
IN
A
L 
O
BS
TR
U
CT
IO
N
RE
SE
CT
IO
N
 A
N
A
ST
O
M
O
SI
S
Y
N
22
3
v
-
-
-
-
24
SU
RE
SH
18
M
19
47
7
LI
V
ER
 L
A
CE
RA
TI
O
N
LA
V
A
G
E 
A
N
D
 D
RA
IN
A
G
E
N
N
22
2
v+
-
-
-
-
25
BA
LA
SU
BR
A
M
A
N
IA
N
50
M
19
70
2
JE
JU
N
A
L 
PE
RF
O
RA
TI
O
N
PR
IM
A
RY
 C
LO
SU
RE
Y
N
27
3
v+
-
-
-
-
26
SA
KU
N
TH
A
LA
33
F
19
74
0
O
BS
TR
U
CT
ED
 H
ER
N
IA
RE
SE
CT
IO
N
 A
N
A
ST
O
M
O
SI
S
N
N
34
2
v+
-
-
-
-
27
SH
A
N
M
U
G
A
V
EL
65
M
20
60
9
IN
TE
ST
IN
A
L 
O
BS
TR
U
CT
IO
N
A
D
H
ES
IO
LY
SI
S
Y
N
22
2
v
+
-
+
-
ot
he
rs
28
CH
EL
LA
PO
O
63
F
21
53
6
IN
TE
ST
IN
A
L 
O
BS
TR
U
CT
IO
N
A
D
H
ES
IO
LY
SI
S
N
N
28
2
v+
-
-
-
-
29
M
A
N
G
A
LA
SU
N
D
A
RI
47
F
21
63
7
IL
EA
L 
PE
RF
O
RA
TI
O
N
PR
IM
A
RY
 C
LO
SU
RE
N
N
27
3
v+
-
-
-
-
30
KR
IS
H
N
A
N
65
M
21
86
3
IN
TE
ST
IN
A
L 
O
BS
TR
U
CT
IO
N
RE
SE
CT
IO
N
 A
N
A
ST
O
M
O
SI
S
Y
N
28
3
v
+
+
-
-
no
 g
ro
w
th
31
SI
V
A
SA
KT
H
IK
U
M
A
R
25
M
22
12
2
PE
RF
O
RA
TI
V
E 
PE
RI
TO
N
IT
IS
O
M
EN
TA
L 
PA
TC
H
N
N
22
4
v
-
-
-
-
32
A
M
LO
O
R 
PA
V
A
M
80
F
23
11
6
IN
TE
ST
IN
A
L 
O
BS
TR
U
CT
IO
N
A
D
H
ES
IO
LY
SI
S
N
N
34
2
v+
-
-
-
-
33
SU
D
A
LA
I M
U
TH
U
27
M
23
41
9
CO
LO
N
IC
 P
ER
FO
RA
TI
O
N
CO
LO
ST
O
M
Y
N
N
22
4
v
+
+
-
-
st
ap
h
34
G
A
N
ES
A
N
45
M
23
48
1
IN
TE
ST
IN
A
L 
O
BS
TR
U
CT
IO
N
RE
SE
CT
IO
N
 A
N
A
ST
O
M
O
SI
S
N
N
29
3
v
-
-
-
-
35
PE
TC
H
IM
U
TH
U
41
M
24
10
8
IL
EA
L 
PE
RF
O
RA
TI
O
N
PR
IM
A
RY
 C
LO
SU
RE
Y
N
33
4
v
-
-
-
-
114 
 
 
36
SI
VA
N
KU
M
AR
76
M
24
86
1
IN
TE
ST
IN
AL
 O
BS
TR
U
CT
IO
N
AD
HE
SI
O
LY
SI
S
Y
N
22
2
v
+
+
-
-
kl
eb
sie
lla
37
N
AR
AY
AN
AN
25
M
25
05
9
IN
TE
ST
IN
AL
 O
BS
TR
U
CT
IO
N
AD
HE
SI
O
LY
SI
S
N
N
26
2
v
-
-
-
-
38
RA
M
AR
19
M
25
46
1
CO
LO
N
IC
 P
ER
FO
RA
TI
O
N
CO
LO
ST
O
M
Y
N
N
21
4
v
-
-
-
-
39
AM
M
AC
HI
38
F
25
57
1
IL
EA
L P
ER
FO
RA
TI
O
N
IL
EO
ST
O
M
Y
N
N
28
3
v
+
-
+
-
no
 g
ro
w
th
40
M
AR
IA
PP
AN
25
M
25
77
3
PE
RF
O
RA
TI
VE
 P
ER
IT
O
N
IT
IS
O
M
EN
TA
L P
AT
CH
N
N
26
4
v+
-
-
-
-
41
SA
KT
HI
 K
AN
N
AN
20
M
27
15
9
IN
TE
ST
IN
AL
 O
BS
TR
U
CT
IO
N
CO
LO
ST
O
M
Y
N
N
29
3
v
-
-
-
-
42
M
U
RU
GE
SA
N
35
M
27
55
2
PE
RF
O
RA
TI
VE
 P
ER
IT
O
N
IT
IS
O
M
EN
TA
L P
AT
CH
N
N
21
4
v+
+
+
-
-
e.
 co
li
43
TH
IM
VA
LI
30
M
27
80
2
LI
VE
R 
LA
CE
RA
TI
O
N
LA
VA
GE
 A
N
D 
DR
AI
N
AG
E
N
N
31
2
v+
-
-
-
-
44
BA
LA
SU
BR
AM
AN
IA
N
53
M
28
07
5
IN
TE
ST
IN
AL
 O
BS
TR
U
CT
IO
N
RE
SE
CT
IO
N
 A
N
AS
TO
M
O
SI
S
N
N
34
3
v
-
-
-
-
45
KA
RT
HI
KA
 S
EL
VI
28
F
28
16
8
IN
TE
ST
IN
AL
 O
BS
TR
U
CT
IO
N
RE
SE
CT
IO
N
 A
N
AS
TO
M
O
SI
S
N
N
29
3
v
+
+
-
-
ot
he
rs
46
PE
RU
M
AL
70
M
28
36
0
PE
RF
O
RA
TI
VE
 P
ER
IT
O
N
IT
IS
O
M
EN
TA
L P
AT
CH
Y
N
22
4
v
-
-
-
-
47
PA
LA
VE
SA
M
25
M
28
54
8
GA
ST
RI
C 
PE
RF
O
RA
TI
O
N
O
M
EN
TA
L P
AT
CH
N
N
27
4
v
-
-
-
-
48
AR
U
M
U
GA
M
24
M
28
98
5
IN
TE
ST
IN
AL
 O
BS
TR
U
CT
IO
N
AD
HE
SI
O
LY
SI
S
N
N
26
2
v+
+
+
-
-
st
ap
h
49
TH
AN
GA
RA
J
52
M
29
92
4
LI
VE
R 
LA
CE
RA
TI
O
N
LA
VA
GE
 A
N
D 
DR
AI
N
AG
E
N
N
32
2
v
-
-
-
-
50
VE
LU
45
M
30
11
3
IN
TE
ST
IN
AL
 O
BS
TR
U
CT
IO
N
RE
SE
CT
IO
N
 A
N
AS
TO
M
O
SI
S
N
N
29
3
v
-
-
-
-
51
PA
RA
M
AS
IV
AM
24
M
30
34
9
PE
RF
O
RA
TI
VE
 P
ER
IT
O
N
IT
IS
O
M
EN
TA
L P
AT
CH
N
N
21
4
v
+
-
+
-
kl
eb
sie
lla
52
SE
ET
HA
RA
M
50
F
31
19
6
PE
RF
O
RA
TI
VE
 P
ER
IT
O
N
IT
IS
O
M
EN
TA
L P
AT
CH
Y
N
32
4
v
-
-
-
53
DU
RA
PA
LL
AM
72
M
31
49
6
IN
TE
ST
IN
AL
 O
BS
TR
U
CT
IO
N
AD
HE
SI
O
LY
SI
S
Y
N
23
2
v
-
-
-
-
54
PA
RV
AT
HI
65
F
30
54
2
IN
TE
ST
IN
AL
 O
BS
TR
U
CT
IO
N
RE
SE
CT
IO
N
 A
N
AS
TO
M
O
SI
S
N
N
34
3
v+
+
+
-
-
e.
 co
li
55
VE
ER
AP
AN
DI
AN
38
M
32
07
9
RE
TR
O
PE
RI
TO
N
EA
L H
EM
AT
O
M
A
LA
VA
GE
 A
N
D 
DR
AI
N
AG
E
N
N
26
2
v
-
-
-
-
56
AY
YA
PI
LL
AI
47
M
32
22
2
PE
RF
O
RA
TI
VE
 P
ER
IT
O
N
IT
IS
O
M
EN
TA
L P
AT
CH
N
N
25
4
v+
-
-
-
-
57
VE
N
KA
TA
RA
M
56
M
31
16
0
GA
ST
RI
C 
PE
RF
O
RA
TI
O
N
GA
ST
RO
JE
JU
N
O
ST
O
M
Y
N
N
25
4
v+
+
+
-
-
no
 g
ro
w
th
58
AY
YA
KU
TT
Y
62
M
32
99
0
IN
TE
ST
IN
AL
 O
BS
TR
U
CT
IO
N
RE
SE
CT
IO
N
 A
N
AS
TO
M
O
SI
S
Y
N
29
3
v+
-
-
-
-
59
HA
RI
HA
RA
SU
BH
U
43
M
33
64
5
PE
RF
O
RA
TI
VE
 P
ER
IT
O
N
IT
IS
O
M
EN
TA
L P
AT
CH
N
N
23
4
v
-
-
-
-
60
KR
IS
HN
AN
65
M
35
44
8
PE
RF
O
RA
TI
VE
 P
ER
IT
O
N
IT
IS
O
M
EN
TA
L P
AT
CH
N
N
32
4
v
+
+
-
-
st
ap
h
61
AA
YI
RA
M
40
M
35
76
6
PE
RF
O
RA
TI
VE
 P
ER
IT
O
N
IT
IS
LA
VA
GE
 A
N
D 
DR
AI
N
AG
E
N
N
27
4
v+
-
-
-
-
62
BA
LA
M
U
RU
GA
N
27
M
39
17
0
IL
EA
L P
ER
FO
RA
TI
O
N
PR
IM
AR
Y 
CL
O
SU
RE
N
N
24
3
v+
-
-
-
-
63
VE
LS
AM
Y
36
M
39
22
9
PE
RF
O
RA
TI
VE
 P
ER
IT
O
N
IT
IS
O
M
EN
TA
L P
AT
CH
N
N
28
4
v+
+
-
+
-
st
ap
h
64
KO
LA
PP
AN
37
M
45
44
2
PE
RF
O
RA
TI
VE
 P
ER
IT
O
N
IT
IS
O
M
EN
TA
L P
AT
CH
N
N
25
4
v+
-
-
-
-
65
SU
DA
LA
IM
U
TH
U
55
M
49
64
0
IN
TE
ST
IN
AL
 O
BS
TR
U
CT
IO
N
RE
SE
CT
IO
N
 A
N
AS
TO
M
O
SI
S
N
N
34
3
v+
-
-
-
-
66
RA
SU
KU
TT
I
50
M
49
71
0
PE
RF
O
RA
TI
VE
 P
ER
IT
O
N
IT
IS
O
M
EN
TA
L P
AT
CH
N
N
24
4
v+
+
+
-
-
kl
eb
sie
lla
67
PI
TC
HA
IA
H
45
M
52
62
1
O
BS
TR
U
CT
ED
 H
ER
N
IA
RE
SE
CT
IO
N
 A
N
AS
TO
M
O
SI
S
N
N
29
3
v+
-
-
-
-
68
AN
AN
D 
KU
M
AR
20
M
54
59
8
PE
RF
O
RA
TI
VE
 P
ER
IT
O
N
IT
IS
O
M
EN
TA
L P
AT
CH
N
N
21
4
v+
-
-
-
-
69
AL
AG
U
RA
J
52
M
54
65
1
IL
EA
L P
ER
FO
RA
TI
O
N
RE
SE
CT
IO
N
 A
N
AS
TO
M
O
SI
S
Y
N
27
4
v+
+
+
-
-
kl
eb
sie
lla
70
AN
N
AD
U
RA
I
43
M
55
35
1
IN
TE
ST
IN
AL
 O
BS
TR
U
CT
IO
N
RE
SE
CT
IO
N
 A
N
AS
TO
M
O
SI
S
Y
N
21
3
v+
-
-
-
-
115 
 
KEY TO MASTER CHART 
M – MALE 
F – FEMALE 
Y – YES 
N – NO 
BMI – BODY MASS INDEX 
+ - POSITIVE 
-  - NEGATIVE 
V – VICRYL 
V+ - VICRYL PLUS 
